

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of May 2012

File No. 000-54598

**Stellar Biotechnologies Inc.**

(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
FORM 20-F  FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.  
(Registrant)

Dated: June 20, 2012

By: /s/ "Darrell Brookstein"  
Darrell Brookstein  
Director

**Exhibits:**

- 99.1 Interim Financial Statements for the period ended February 29, 2012**
- 99.2 Management Discussion and Analysis**
- 99.3 Certification of CEO**
- 99.4 Certification of CFO**



Condensed Interim Consolidated Financial Statements  
 For the Six Months Ended February 29, 2012

(In US Dollars)

Unaudited - Prepared by Management

**NOTICE OF NO AUDITOR REVIEW OF**

**CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS**

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Canadian Institute of Chartered Accountants for a review of interim financial statements by an entity's auditor.

**Stellar Biotechnologies, Inc**

Notes to Condensed Interim Consolidated Financial Statements

Unaudited – Prepared by Management

For the Six Months Ended February 29, 2012

(in US Dollars)

	<b>February 29, 2012</b>	August 31, 2011	September 1, 2010
		(Note 15)	(Note 15)
<b>Assets:</b>			
Current assets:			
Cash and cash equivalents	<b>\$ 2,945,496</b>	\$ 4,145,492	\$ 2,003,296
Accounts receivable (Note 4)	<b>31,611</b>	39,021	568,495
Prepaid expenses	<b>8,207</b>	36,604	22,940

Total current assets	<b>2,985,314</b>	4,221,117	2,594,731
Noncurrent assets:			
Biological assets (Note 11)	<b>6,185</b>	5,763	3,173
Property, plant and equipment (Note 6)	<b>309,806</b>	338,224	89,577
Licensing rights (Note 7)	<b>159,524</b>	173,810	200,000
Deposits	<b>17,500</b>	17,500	8,766
Total noncurrent assets	<b>493,015</b>	535,297	301,516
Total Assets	<b>\$ 3,478,329</b>	\$ 4,756,414	\$ 2,896,247
<b>Liabilities and Shareholders' Equity:</b>			
Current liabilities:			
Accounts payable and accrued liabilities	<b>\$ 263,151</b>	\$ 159,137	\$ 420,610
Deferred revenue	<b>47,383</b>	-	-
Total current liabilities	<b>310,534</b>	159,137	420,610
Long-term liabilities:			
Warrant liability (Note 10)	<b>361,797</b>	1,527,374	797,310
Total Liabilities	<b>672,331</b>	1,686,511	1,217,920
Shareholders' Equity:			
Share capital (Note 10)	<b>10,290,573</b>	9,269,433	2,364,254
Share-based payment reserve (Note 10)	<b>972,440</b>	734,524	369,438
Deficit	<b>(8,457,015)</b>	(6,934,054)	(1,055,365)
Total shareholders' equity	<b>2,805,998</b>	3,069,903	1,678,327
Total Liabilities and Shareholders' Equity	<b>\$ 3,478,329</b>	\$ 4,756,414	\$ 2,896,247
Nature and Continuance of Operations (Note 1)			
Commitments (Note 8)			
Events after the Reporting Period (Note 13)			

These condensed interim consolidated financial statements were approved for Issuance by the Board of Directors on April 30, 2012 and are signed on its behalf by:

Director Signed: "Frank Oakes"

Director Signed: "Daniel Morse"

The accompanying notes are an integral part of these condensed interim consolidated financial statements

## Stellar Biotechnologies, Inc

Condensed Interim Consolidated Statements of Comprehensive Loss

(Unaudited – Prepared by Management)

(in US Dollars)

	Three Months Ended		Six Months Ended	
	February 29, 2012	February 28, 2011	February 29, 2012	February 28, 2011
<b>Revenues:</b>				
Contract income	<b>\$ 15,000</b>	\$ 15,000	<b>\$ 30,000</b>	\$ 30,000
Commercial sales	<b>13,575</b>	4,200	<b>113,925</b>	9,838
Grant revenue	<b>29,665</b>	526,217	<b>49,682</b>	575,475
	<b>58,240</b>	545,417	<b>193,607</b>	615,313
<b>Cost of Production, Aquaculture and Grants:</b>				
Costs of production and aquaculture (Note 11)	<b>115,962</b>	136,257	<b>324,133</b>	250,500
Grant costs	<b>28,913</b>	33,084	<b>51,779</b>	62,358
	<b>144,875</b>	169,341	<b>375,912</b>	312,858
<b>Gross Margin (Loss)</b>	<b>(86,635)</b>	376,076	<b>(182,305)</b>	302,455
<b>Expenses:</b>				

Salaries, wages and benefits	298,579	275,115	533,563	376,832
Research and development	388,794	295,525	956,409	578,180
Legal and professional services	126,052	63,030	230,633	154,071
Share-based payments (Note 10)	(39,802)	3,506,798	237,916	3,620,659
General and administration	266,588	161,469	446,755	296,471
Amortization and depreciation	27,244	16,022	54,309	29,152
Allocation of expenses to grant costs	(12,288)	(10,632)	(23,047)	(23,126)
	<u>1,055,167</u>	<u>4,307,327</u>	<u>2,436,538</u>	<u>5,032,239</u>
<b>Other Income:</b>				
Loss recovery (Note 16)	-	-	105,000	-
Foreign exchange gain (loss)	35,705	91,053	13,640	6,511
Change in fair value of warrant liability (Note 10)	261,217	772,702	975,152	(4,485,746)
Interest income	971	3,046	2,890	5,008
	<u>297,893</u>	<u>866,801</u>	<u>1,096,682</u>	<u>(4,474,227)</u>
<b>Loss Before Income Tax</b>	<b>(843,909)</b>	<b>(3,064,450)</b>	<b>(1,522,161)</b>	<b>(9,204,011)</b>
Income tax expense	800	-	800	5,000
	<u>(844,709)</u>	<u>(3,064,450)</u>	<u>(1,522,961)</u>	<u>(9,209,011)</u>
<b>Loss and Comprehensive Loss for the Period</b>	<b>(844,709)</b>	<b>(3,064,450)</b>	<b>(1,522,961)</b>	<b>(9,209,011)</b>
Loss per common share –basic and diluted	<u>\$ (0.02)</u>	<u>\$ (0.08)</u>	<u>\$ (0.04)</u>	<u>\$ (0.27)</u>
Weighted average number of common shares outstanding	<u>43,930,431</u>	<u>38,782,207</u>	<u>43,497,683</u>	<u>34,559,364</u>

The accompanying notes are an integral part of these condensed interim consolidated financial statements

## Stellar Biotechnologies, Inc

### Condensed Interim Consolidated Statements of Cash Flows

(Unaudited – Prepared by Management)

(in US Dollars)

	<b>Six Months Ended</b>	
	<b>February 29, 2012</b>	<b>February 28, 2011</b>
<b>Cash Flows From (Used In) Operating Activities:</b>		
Loss for the period	\$ (1,522,961)	\$ (9,209,011)
Items not affecting cash:		
Amortization and depreciation	54,309	29,152
Share-based payments	237,916	3,620,659
Foreign exchange (gain) loss	(13,328)	(6,000)
Change in fair value of warrant liability	(975,152)	4,485,746
Remeasurement of biological assets	(422)	(3,092)
Changes in non-cash working capital items:		
Accounts receivable	21,050	552,137
Prepaid expenses	28,397	(7,471)
Accounts payable and accrued liabilities	104,014	(180,964)
Deferred revenue	47,383	-
Net cash used in operating activities	<u>(2,018,794)</u>	<u>(718,844)</u>
<b>Cash Flows From (Used In) Financing Activities:</b>		
Proceeds from exercise of warrants	830,715	669,906
Share subscription proceeds	-	4,729,524
Share issuance costs	-	(312,103)
Repurchase dissenting shareholder shares	-	(125,025)
Payment of deposits	-	(1,600)
Net cash provided by financing activities	<u>830,715</u>	<u>4,960,702</u>
<b>Cash Flows From (Used In) Investing Activities:</b>		
Acquisition of property, plant and equipment	<u>(11,605)</u>	<u>(245,751)</u>
Net cash used in investing activities	<u>(11,605)</u>	<u>(245,751)</u>
Effect of exchange rate changes on cash and cash equivalents	<u>(312)</u>	<u>(511)</u>

Net change in cash and cash equivalents	<b>(1,199,996)</b>	3,995,596
Cash and cash equivalents – beginning of period	<b>4,145,492</b>	2,003,296
Cash and cash equivalents – end of period	<b>\$ 2,945,496</b>	<b>\$ 5,998,892</b>
Cash	<b>\$ 1,337,282</b>	\$ 5,998,892
Cash equivalents	<b>1,608,214</b>	-
Cash and cash equivalents	<b>\$ 2,945,496</b>	<b>\$ 5,998,892</b>

Supplemental disclosure of non-cash transactions (*Note 12*)

The accompanying notes are an integral part of these condensed interim consolidated financial statements

## Stellar Biotechnologies, Inc

Condensed Interim Consolidated Statements of Changes to Equity  
(Unaudited – Prepared by Management)  
(in US Dollars)

	Number of Shares	Share Capital	Share-based Payment Reserve	Deficit	Total
<b>Balance - September 1, 2010</b>	26,916,692	\$ 2,364,254	\$ 369,438	\$ (1,055,365)	\$ 1,678,327
Private placements, net of issuance costs	9,213,000	1,137,103			1,137,103
issuance of performance shares	3,333,335	3,400,000			3,400,000
Proceeds from exercise of warrants	1,921,305	691,139			691,139
Transfer to share capital on exercise of warrants		1,213,969			1,213,969
Final settlement of dissenting shareholder		(4,222)			(4,222)
Share-based payments			220,659		220,659
Loss for the period				(9,209,011)	(9,209,011)
<b>Balance – February 28, 2011</b>	41,384,332	\$ 8,802,243	\$ 590,097	\$ (10,264,376)	\$ (872,036)
<b>Balance – August 31, 2011</b>	41,611,832	\$ 9,269,433	\$ 734,524	\$ (6,934,054)	\$ 3,069,903
Proceeds from exercise of warrants	2,318,600	830,715			830,715
Transfer to share capital on exercise of warrants		190,425			190,425
Share-based payments			237,916		237,916
Loss for the period				(1,522,961)	(1,522,961)
<b>Balance – February 29, 2012</b>	43,930,432	\$ 10,290,573	\$ 972,440	\$ (8,457,015)	\$ 2,805,998

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited – Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### 1. Nature and Continuance of Operations

Stellar Biotechnologies, Inc. (“the Company”, formerly CAG Capital Inc.) is listed on the TSX Venture Exchange (“the Exchange”) as a Tier 2 issuer under the trading symbol KLH since April 19, 2010 (formerly under CAG.P).

On April 7, 2010, the Company changed its name to Stellar Biotechnologies, Inc. On April 12, 2010, the Company completed a reverse merger transaction with Stellar Biotechnologies, Inc. (“Stellar CA”) which is incorporated under the laws of the State of California, USA. The Company’s head office is 332 E. Scott Street, Port Hueneme, California, 93041, USA, and the registered office is 1868 King George Boulevard, South Surrey, BC, V4A 5A1, Canada.

The Company’s business is to commercially produce and market Keyhole Limpet Hemocyanin (“KLH”) as well as to develop new technology related to culture and production of KLH and subunit KLH (“suKLH”) formulations. The Company markets KLH and

suKLLH formulations to customers in the United States and Europe.

The Company has received grants for the development of new technology from the National Institutes of Health, National Cancer Institute (“NIH”), the National Science Foundation (“NSF”) including grants under its Technology Enhancement for Commercial Partnerships (“TECP”) program, and Internal Revenue Service (“IRS”) qualifying therapeutic discovery project grants.

These condensed interim consolidated financial statements are prepared on a going concern basis. The going concern basis contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. Should the Company be required to realize the value of its assets in other than the ordinary course of business, the net realizable value of its assets may be materially less than the amounts shown in the condensed interim consolidated financial statements. For the period ended February 29, 2012, the Company reported a loss of \$1,552,961 (2011 - \$9,209,011), an accumulated deficit of \$8,457,015 (August 31, 2011 - \$6,934,054; September 1, 2010 - \$1,055,365) and working capital of \$2,674,780 (August 31, 2011 - \$4,061,980; September 1, 2010 - \$2,174,121). As at February 29, 2012, the Company has remaining revenues available under the NSF grants, including the Technology Enhancement for Commercial Partnerships (“TECP”) program of approximately \$490,000. The Company also anticipates ongoing contract income and commercial sales.

The financial statements of the Company are presented in US dollars, unless otherwise stated, which is the presentation currency.

## 2. Basis of Presentation and Adoption of IFRS

### *Statement of Compliance and Conversion to International Financial Reporting Standards*

These unaudited condensed interim consolidated financial statements, including comparatives have been prepared using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”) and in accordance with International Accounting Standard (“IAS”) 34, Interim Financial Reporting.

The preparation of these condensed interim consolidated financial statements resulted in changes to the accounting policies as compared with the most recent annual financial statements prepared under Canadian Generally Accepted Accounting Principles (“Canadian GAAP”). The accounting policies set out below have

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

## 2. Basis of Presentation and Adoption of IFRS (continued)

been applied consistently to all periods presented in these condensed interim consolidated financial statements. They have also been applied in preparing an opening IFRS balance sheet as at September 1, 2010 for the purposes of the transition to IFRS, as required by IFRS 1, First Time Adoption of International Financial Reporting Standards (“IFRS 1”). The impact of the transition from Canadian GAAP to IFRS is explained in Note 15.

As these are the Company’s second condensed interim consolidated financial statements prepared in accordance with IFRS, the Company’s disclosures exceed the minimum requirements under IAS 34. The Company has elected to exceed the minimum requirements in order to present the Company’s accounting policies in accordance with IFRS and the additional disclosures required under IFRS, which also highlight the changes from the Company’s August 31, 2011 annual consolidated financial statements prepared in accordance with Canadian GAAP. In fiscal year August 31, 2013 and beyond, the Company may not provide the same amount of disclosure in the Company’s condensed interim consolidated financial statements under IFRS as the reader will be able to refer to the August 31, 2012 annual consolidated financial statements which will be prepared in accordance with IFRS.

### *Basis of Presentation*

The condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit or loss, which are stated at their fair value. In addition, these financial statements have been prepared using the accrual basis of accounting except for cash flow information.

The preparation of these condensed interim consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the period. Actual results could differ from these estimates.

These condensed interim consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the condensed interim consolidated financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical

experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

### 3. Significant Accounting Policies

The accounting policies set out below are expected to be adopted for the year-ending August 31, 2012 and have been applied consistently to all periods presented in these condensed interim consolidated financial statements and in preparing the opening IFRS statement of financial position at September 1, 2010 for the purposes of the transition to IFRS, unless otherwise indicated.

#### a) Principles of Consolidation

The condensed interim consolidated financial statements have been prepared in accordance with IFRS and include the accounts of the Company and its wholly-owned subsidiary Stellar Biotechnologies, Inc. ("Stellar CA"). Intercompany balances and transactions are eliminated on consolidation.

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 3. Significant Accounting Policies (continued)

#### b) Use of Estimates

The preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported periods. The Company has made estimates for allowance of doubtful accounts, amortization and depreciation and impairment of property, plant and equipment and licensing rights, share-based payments, research and development costs, biological assets, the provision for deferred income tax recoveries and composition of deferred income tax assets and liabilities, and accrued liabilities. Actual results could differ from these estimates.

Significant assumptions about the future and other sources of estimated uncertainty that management has made at the financial position reporting date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to the following:

- 1) the inputs used in the accounting for share-based payment expense included in profit or loss.
- 2) the inputs used in accounting for biological assets included in statements of financial position and profit or loss.
- 3) the determination of the useful life of the licensing rights.
- 4) the inputs used in the accounting for the warrant liability.

#### c) Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period.

The computation of diluted loss per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on loss per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the "if converted" method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method.

#### d) Share-Based Payments

The Company grants share options to buy common shares of the Company to directors, officers, employees and consultants. An individual is classified as an employee when the individual is an employee for legal or tax purposes, or provides services similar to those performed by an employee.

For employees, the fair value of share options is measured on the date of grant, using the Black-Scholes option pricing model and is recognized over the vesting period using graded vesting. Consideration paid for the shares on the exercise of share options is credited to share capital and the related share-based compensation is reclassified from the share-based payment reserve to share capital. When vested options are forfeited or are not exercised at the expiry date the amount previously recognized in share-based payment reserve is transferred to accumulated losses (deficit).

In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at fair value of

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 3. Significant Accounting Policies (continued)

the share-based payment. Otherwise, share-based payments are measured at the fair value of goods and services rendered.

#### e) Property, Plant and Equipment

Property, plant and equipment are recorded at cost less accumulated depreciation. Depreciation is recorded on the straight-line method based on the following rates which approximate the useful life of the assets:

Aquaculture system	10-20%
Tools and equipment	20%
Leasehold improvements	10-14%
Laboratory	10-20%
Computer and office equipment	20%
Vehicles	20%

Maintenance and repairs are charged to operations as incurred.

#### f) Cash and Cash Equivalents

Cash equivalents consist of demand deposits with financial institutions, money market accounts, and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased.

#### g) Income Taxes

Income tax expense comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes, the initial recognition of assets and liabilities that affect neither accounting nor taxable loss, and differences relating to investments in subsidiaries to the extent that they will be probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it probable that a deferred tax asset will be recovered, it provides a valuation allowance against that excess.

#### h) Financial Instruments

Financial assets are classified into one of the following categories based on the purpose for which the asset was acquired. All transactions related to financial instruments are recorded on a trade date basis. The Company's accounting policy for each category is as follows:

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 3. Significant Accounting Policies (continued)

#### *Financial assets at fair value through profit or loss ("FVTPL")*

A financial asset is classified at fair value through profit or loss if it is classified as held for trading or is designated as such upon initial recognition. Financial assets are designated as at FVTPL if the Company manages such investments and makes purchase and sale decisions based on their fair value in accordance with the Company's risk management strategy. Attributable transaction costs are recognized in profit or loss when incurred. FVTPL are measured at fair value, and changes are recognized in profit or loss.



### *Held-to-maturity (“HTM”)*

These assets are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Company’s management has the positive intention and ability to hold to maturity. These assets are measured at amortized costs using the effective interest method. If there is objective evidence that the asset is impaired, determined by reference to external credit ratings and other relevant indicators, the financial asset is measured at the present value of estimated future cash flows. Any changes to the carrying amount of the investment, including impairment losses, are recognized in profit or loss.

### *Loans and receivables*

Loans and receivables are financial assets with fixed or determinable payments that are not quoted on an active market. Such assets are initially recognized at fair value plus any direct attributable transaction costs. Subsequent to initial recognition loans and receivables are measured at amortized cost using the effective interest method, less any impairment loss.

### *Available for sale (“AFS”)*

Non-derivative financial assets not included in the above categories are classified as available-for-sale. They are carried at fair value with changes in fair value recognized directly in equity. Where a decline in the fair value of an available-for-sale financial asset constitutes objective evidence of impairment, the amount of the loss is removed from equity and recognized in profit or loss.

The Company has classified its financial assets as follows:

- Cash and cash equivalents are classified as FVTPL.
- Accounts receivable are classified as loans and receivables.

### *Financial liabilities*

All financial liabilities are initially recorded at fair value. Financial liabilities are classified into one of the following two categories:

#### *Fair value through profit or loss (“FVTPL”)*

This category comprises derivatives, or liabilities, acquired or incurred principally for the purpose of selling or repurchasing it in the near term. They are carried in the statement of financial position at fair value with changes in fair value recognized in profit or loss.

Warrants which do not meet the criteria to be classified as an equity instrument are classified as fair value through profit or loss financial liabilities.

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### **3. Significant Accounting Policies (continued)**

#### *Other financial liabilities*

Financial liabilities classified as other financial liabilities are measured at amortized cost.

The Company has classified its financial liabilities as follows:

- Accounts payable is classified as other financial liabilities.
- Warrant liability is classified as FVTPL.

#### *Impairment of financial assets*

Financial assets, other than those at FVTPL, are assessed for indicators of impairment at the end of each reporting period. Financial assets are impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial assets, the estimated future cash flows of the assets have been impacted.

For all financial assets objective evidence of impairment could include:

- significant financial difficulty of the issuer or counterparty; or
- default or delinquency in interest or principal payments; or
- it becoming probable that the borrower will enter bankruptcy or financial re-organization.

i) Impairment of Tangible and Intangible Assets

At the end of each reporting period, the Company's assets are reviewed to determine whether there is any indication that those assets may be impaired. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment, if any. The recoverable amount is the higher of fair value less costs to sell and value in use. Fair value is determined as the amount that would be obtained from the sale of the asset in an arm's length transaction between knowledgeable and willing parties. In assessing value in use, the estimated future cash flows are discounted to their present value using pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount and the impairment loss is recognized in profit or loss for the period. For an asset that does not generate largely independent cash flows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but to an amount that does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

j) Biological Assets

Biological assets are keyhole limpets which are bearer assets to produce KLH. They are measured at fair value less costs to sell. Fair value is based on market prices of mature keyhole limpets which are harvested from the ocean. The Company expenses the costs of aquaculture. Fair value gains and losses are determined upon remeasurement at each reporting period. Biological assets include production limpets and dedicated limpet colonies under contract.

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### **3. Significant Accounting Policies (continued)**

k) Research and Development

The Company is involved in research and development. Research costs, including materials and salaries of employees directly involved in research efforts, are expensed as incurred. Development costs are expensed in the period incurred, unless they meet criteria for technical, market and financial feasibility, in which case they are deferred and amortized over the estimated life of related products. Research and development expenses are shown as a separate line item on the consolidated statements of comprehensive loss. As at February 29, 2012, the Company had no deferred development costs.

l) Foreign Exchange

Items included in the financial statements of the Company's subsidiary are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The functional currency of the parent and its subsidiary is the US dollar.

Transactions in currencies other than the US dollar are recorded at exchange rates prevailing on the dates of the transactions. At the end of each reporting period, monetary assets and liabilities denominated in foreign currencies are translated at the period end exchange rate while non-monetary assets and liabilities are translated at historical rates. Revenues and expenses are translated at the exchange rates approximating those in effect on the date of the transactions. Exchange gains and losses arising on translation are included in comprehensive loss.

m) Commercial Sales Revenue Recognition

The Company recognizes commercial sales revenue when KLH product is delivered assuming there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. In limited circumstance, the Company retains ownership until the product is received and inspected by the customer; revenue is recognized upon satisfaction of these conditions. The Company documents arrangements with customers with purchase orders and sales agreements.

Commercial sales revenue includes sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered, including those produced from the customer's dedicated limpet colonies. The supply agreements are on a non-exclusive basis except within that customer's field of use.

n) Grant Revenue Recognition

The Company has taken the income approach to recognizing grant revenue. The Company recognizes grant revenue when there is reasonable assurance that the Company will comply with the conditions attached, the benefits have been earned and it is reasonably assured of collection. An appropriate amount in respect to earned revenue will be recognized as revenue in the period that the Company is assured of fulfilling the grant requirements. Grant advances received prior to revenue recognition are recorded as deferred revenue.

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### **3. Significant Accounting Policies (continued)**

#### **o) Contract Income Recognition**

Contract income is recognized when reasonable assurance exists regarding measurement and collectability. An appropriate amount in respect to earned revenue will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements.

Contract income is earned on both the initial set up fee for establishment of limpet colonies dedicated to meet the needs of the customer and monthly fees to maintain those dedicated limpet colonies. The Company also has the right to use raw material produced from dedicated limpet colonies at no cost with prior written consent.

Contract income is earned from research collaboration agreements whereby revenue is earned through sharing access to the Company's KLH manufacturing methods and analytical data as well as when certain project milestones are met. The customer and the Company will jointly own the rights to practice the resulting intellectual properties within specified fields of use.

#### **p) Accounting Standards Issued But Not Yet Applied**

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company has not early adopted any of these standards and is currently evaluating the impact, if any, that these standards might have on its financial statements.

#### **Accounting Standards Issued and Effective January 1, 2013**

IFRS 9 *Financial Instruments* replaces the current standard IAS 39 *Financial Instruments: Recognition and Measurement*, replacing the current classification and measurement criteria for financial assets and liabilities with only two classification categories: amortized cost and fair value.

IFRS 10 *Consolidated Financial Statements* establishes principles for the presentation and preparation of consolidated financial statements when an entity controls one or more other entities. IFRS 10 supersedes IAS 39, *Financial Instruments: Recognition and Measurement*.

IFRS 11 *Joint Arrangements* establishes the core principle that a party to a joint arrangement determines the type of joint arrangement in which it is involved by assessing its rights and obligations and accounts for those rights and obligations in accordance with that type of joint arrangement.

IFRS 12 *Disclosure of Involvement with Other Entities* requires the disclosure of information that enables users of financial statements to evaluate the nature of, and risks associated with, its interests in other entities and the effects of those interests on its financial position, financial performance and cash flows.

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### **3. Significant Accounting Policies (continued)**

IFRS 13 *Fair Value Measurement* defines fair value, sets out in a single IFRS framework for measuring fair value and requires disclosures about fair value measurements. IFRS 13 applies when another IFRS requires or permits fair value measurements or disclosures about fair value measurements (and measurements, such as fair value less costs to sell, based on fair value or

disclosures about those measurements), except for: share-based payment transactions within the scope of IFRS 2 Share-based Payment; leasing transactions within the scope of IAS 17 Leases; measurements that have some similarities to fair value but that are not fair value, such as net realizable value in IAS 2 Inventories or value in use in IAS 36 Impairment of Assets.

IAS 27 *Separate Financial Statement (Amended)* has the objective of setting standards to be applied in accounting for investments in subsidiaries, joint ventures, and associates when an entity elects, or is required by local regulations, to present separate (non-consolidated) financial statements.

IAS 28 *Investments in Associates and Joint Ventures (Amended)* prescribes the accounting for investments in associates and sets out the requirements for the application of the equity method when accounting for investments in associates and joint ventures. IAS 28 applies to all entities that are investors with joint control of, or significant influence over, an investee (associate or joint venture).

#### 4. Accounts Receivable

	February 29, 2012	August 31, 2011	September 1, 2010
Accounts receivable	\$ 26,611	\$ 6,446	\$ 223,283
Contract receivable	5,000	5,000	255,000
Grants receivable		27,575	90,212
	<u>\$ 31,611</u>	<u>\$ 39,021</u>	<u>\$ 568,495</u>

#### 5. Financial Instruments

The Company is exposed to various financial instrument risks and assesses the impact and likelihood of this exposure. These risks include liquidity risk, credit risk, currency risk and interest rate risk. Where material, these risks are reviewed and monitored by the Board of Directors.

##### Capital Management

The Company manages its capital to safeguard the Company's ability to continue as a going concern, so that it can continue to provide adequate returns to shareholders and benefits to other stakeholders, and to have sufficient funds on hand for business opportunities as they arise.

The Company considers the items included in share capital as capital. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through short-term prospectuses, private placements, sell assets, incur debt, or return capital to shareholders. As at February 29, 2012, the Company does not have any debt and is not subject to externally imposed capital requirements.

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

#### 5. Financial Instruments (continued)

##### Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate as a result in market interest rates. The Company is exposed to interest rate risk to the extent that the cash maintained at the financial institutions included in the Company's cash and cash equivalents are subject to a floating rate of interest.

The interest rate risks on cash are not considered significant.

##### Foreign Exchange Risk

The Company incurs operating expenses and capital expenditures mostly in US dollars, with some operating expenses incurred in Canadian dollars which are subject to foreign currency fluctuations. The fluctuation of the US dollar in relation to Canadian dollars will have an impact upon the profitability of the Company and may also affect the value of the Company's assets and the amount of shareholders' equity. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. At February 29, 2012, the US dollar was equal to 0.99656 Canadian dollars. The currency risk is considered to be insignificant.

##### Credit Risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. Management's assessment of the Company's credit risk for cash and cash equivalents is low as cash and cash equivalents are held in financial institutions believed to be credit worthy. The Company limits its exposure to credit loss by placing its cash with major financial institutions and invests only in short-term obligations.

Approximately 99% of the Company's commercial sales and contract income during the period ended February 29, 2012 were from two customers (2011 - 86% from one customer,). All of the grant revenue during the period ended February 29, 2012 was received from NSF (2011 - 81% from IRS grants and 19% from NSF).

Approximately 81% of the Company's accounts receivables at February 29, 2012, were from one customer (August 31, 2011 - 25% from two customers, September 1, 2010 - 84% from two customers), and \$Nil were from the NSF grants (August 31, 2011 - 75%, September 1, 2010 - 16%).

While the Company is exposed to credit losses due to the non-performance of its counterparties, the Company considers the risk of this remote. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet.

### Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company attempts to manage liquidity risk by maintaining sufficient cash and cash equivalent balances. Liquidity requirements are managed based on expected cash flows to ensure that there is sufficient capital in order to meet short term obligations. As at February 29, 2012, the Company had a cash and cash equivalents balance of \$2,945,496 (August 31, 2011 - \$4,145,492, September 1, 2010 - \$2,003,296) to settle current liabilities of \$310,534 (August 31, 2011 - \$159,137, September 1, 2010 - \$420,610).

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited - Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### **5. Financial Instruments (continued)**

#### Fair Value

The fair value of the Company's financial instruments is believed to equal the carrying amounts due to the short terms to maturity.

Fair value measurement disclosures include classification of financial instrument fair values in a fair value hierarchy comprising three levels reflecting the significance of the inputs used in making the measurements, described as follows:

- Level 1: Valuations based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: Valuations based on directly or indirectly observable inputs in active markets for similar assets or liabilities, other than Level 1 prices such as quoted interest or currency exchange rates; and
- Level 3: Valuations based on significant inputs that are not derived from observable market data, such as discounted cash flow methodologies based on internal cash flow forecasts.

The Company's fair value of cash and cash equivalents under the fair value hierarchy is measured using Level 1 inputs and fair value of the warrant liability is measured using Level 2 inputs.

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited - Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### **6. Property, Plant and Equipment**

Cost:	Aquaculture System	Laboratory	Computer and Office Equipment	Tools and Equipment	Vehicles	Leasehold Improvements	Total PP&E
Balance - September 1, 2010	\$ 43,241	\$ 62,033	\$ 16,628	\$ 93,689	\$ -	\$ 28,015	\$ 243,606

Additions	4,529		16,567	246,597	10,997	31,092	309,782
Balance – August 31, 2011	\$ 47,770	\$ 62,033	\$ 33,195	\$ 340,286	\$ 10,997	\$ 59,107	\$ 553,388
Additions			6,075	5,532			11,607
Balance – February 29, 2012	\$ 47,700	\$ 62,033	\$ 39,270	\$ 345,818	\$ 10,997	\$ 59,107	\$ 564,995
<b>Accumulated depreciation:</b>			<b>Computer and Office Equipment</b>	<b>Tools and Equipment</b>	<b>Vehicles</b>	<b>Leasehold Improvements</b>	<b>Total PP&amp;E</b>
Balance – September 1, 2010	\$ (43,241)	\$ (62,033)	\$ (1,826)	\$ (18,914)	\$ -	\$ (28,015)	\$ (154,029)
Additions	(302)		(4,858)	(53,381)	(1,100)	(1,494)	(61,135)
Balance – August 31, 2011	\$ (43,543)	\$ (62,033)	\$ (6,684)	\$ (72,295)	\$ (1,100)	\$ (29,509)	\$ (215,164)
Additions	(453)		(3,768)	(32,135)	(1,100)	(2,569)	(40,025)
Balance – February 29, 2012	\$ (43,996)	\$ (62,033)	\$ (10,452)	\$ (104,430)	\$ (2,200)	\$ (32,078)	\$ (255,189)
<b>Carrying Value:</b>			<b>Computer and Office Equipment</b>	<b>Tools and Equipment</b>	<b>Vehicles</b>	<b>Leasehold Improvements</b>	<b>Total PP&amp;E</b>
Balance – September 1, 2010	\$ -	\$ -	\$ 14,802	\$ 74,775	\$ -	\$ -	\$ 89,577
Balance – August 31, 2011	\$ 4,227	\$ -	\$ 26,511	\$ 267,991	\$ 9,897	\$ 29,598	\$ 338,224
Balance – February 29, 2012	\$ 3,774	\$ -	\$ 28,818	\$ 241,388	\$ 8,797	\$ 27,029	\$ 309,806

## 7. Licensing Rights

During 2010 the Company paid a \$200,000 license fee for intellectual property arising under a research collaboration agreement to a customer for licensing rights outside the customer's field of use. The customer and the Company will jointly own the rights to practice the resulting intellectual properties within specified fields of use. The license rights are amortized over the useful life of seven years.

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

## 7. Licensing Rights (continued)

	Licensing Rights	Accumulated Amortization	Carrying Amount
Balance – September 1, 2010	\$ 200,000	\$ -	\$ 200,000
Balance – February 28, 2011	200,000	-	200,000
Amortization expense		(26,190)	(26,190)
Balance at August 31, 2011	200,000	(26,190)	173,810
Amortization expense		(14,286)	(14,286)
Balance at February 29, 2012	\$ 200,000	\$ (40,476)	\$ 159,524

## 8. Commitments

The Company leases three buildings and facilities under sublease agreements with the Port Hueneme Surplus Property Authority. On September 1, 2010, the Company exercised its option to extend the three buildings and facilities sublease agreements. The monthly base rents total \$7,071 effective November 1, 2010, for a term of 5 years with rents adjusted by the CPI index every November 1st. The Company has an option to extend the lease for another five years.

The Company also leases office facilities effective July 1, 2011 for a term of three years with the option to extend for an additional two years. Rent is \$5,126 per month with 3% cost of living increases each year during the initial three-year term and the Company must pay a portion of the common area maintenance.

Future minimum lease payments are as follows:

<u>For The Year Ending August 31,</u>	<u>February 29, 2012</u>	<u>August 31, 2011</u>
2012	\$ 73,492	\$ 146,676
2013	148,531	148,531
2014	139,328	139,328
2015	84,852	84,852
2016	14,142	14,142
	<u>\$ 460,345</u>	<u>\$ 533,529</u>

Rent expense on these lease agreements for the period ended February 29, 2012 was \$85,231 (2011 - \$49,200).

The Company has purchase order commitments totalling approximately \$89,000 at February 29, 2012, for contract manufacturing organizations and consultants (August 31, 2011 - \$184,000, September 1, 2010 - \$117,000).

The Company has commitments under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer's field of use.

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### **9. Related Party Transactions**

For the period ended February 29, 2012, the Company had the following transactions with related parties:

- a) Paid or accrued salaries and benefits expense of \$358,425 (2011 - \$332,714) to directors and officers of the Company and their family members;
- b) Paid or accrued director fees of \$16,600 (2011 - \$2,000) to directors of the Company;
- c) Paid or accrued consulting fees of \$28,750 (2011 - \$24,910) to directors and officers of the Company;
- d) Paid or accrued professional fees of \$35,058 (2011 - \$Nil) to an officer of the Company;
- e) Paid or accrued professional fees of \$Nil (2011 - \$10,500) to a former officer of the Company.
- f) The share-based payments to directors, family members of directors and officers of the Company during the period ended February 29, 2012 was \$140,345 (2011 - \$149,999). Share-based payments are the fair value of the options granted.

As at February 29, 2012, the Company owed \$7,829 (2011 - \$Nil) to directors and officers of the Company for consulting fees and expense reimbursements which are included in accounts payable and accrued liabilities on the consolidated balance sheets.

On August 14, 2002, the Company entered into an agreement to pay royalties to a director and officer in exchange for assignment of patent rights to the Company. The royalty is 5% of gross receipts in excess of \$500,000 annually from products using this invention. The Company's current operations utilize this invention. The royalties for the period ended February 29, 2012 were \$Nil (2011 - \$Nil).

### **10. Share Capital**

Authorized: unlimited common shares without par value.

#### Private Placements Issued During the Year Ended August 31, 2011

- (a) In September 2010, the Company issued 3,000,000 units at a price of CDN\$0.35 per unit for gross proceeds of \$1,002,497 (CDN\$1,050,000). Each unit is comprised of one common share of the Company and one half share purchase warrant. Each full warrant entitles the holder to purchase one common share of the Company at a price of CDN\$0.50 exercisable on or before March 28, 2012. The warrants were valued at \$291,949. Agent's options were issued to acquire 210,000 units of the Company (valued at \$49,861) under the same terms of the private placement and are exercisable at CDN\$0.35 on or before March 28, 2012. The common shares are subject to the Exchange four month hold policy which ended on January 30, 2011. The company paid \$96,958 of share issuance costs in relation to the private placement.
- (b) In November 2010, the Company issued 6,213,000 units at a price of CDN\$0.60 per unit for gross proceeds of \$3,695,784 (CDN\$3,727,800). Each unit is comprised of one common share of the Company and one share purchase warrant. Each warrant entitles the holder to purchase one common share of the Company at a purchase price of CDN\$0.90 per share on or before November 14, 2011, and CDN\$1.15 per share if exercisable from November 15, 2011, and on or before November 14,

2012. The warrants were valued at \$2,711,921. Agent's options were issued to acquire 345,600 units of the Company (valued at \$226,587) under the same terms of the private placement and are exercisable at CDN\$0.60 on or before November 14, 2012. The common shares are subject to the Exchange four month hold policy which ended on March 16, 2011. The Company paid \$215,145 of share issuance costs in relation to the private placement.

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited – Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### 10. Share Capital (continued)

#### Escrow Shares

An aggregate of 2,500,000 common shares were held in escrow pursuant to an Escrow Agreement dated April 29, 2008. Of these shares, as at February 29, 2012, 1,125,000 shares remain in escrow.

Of the 10,000,000 common shares issued pursuant to the reverse takeover, an aggregate of 4,119,386 common shares were held in escrow pursuant to an Escrow Agreement dated April 7, 2010. The shares are subject to release provisions, with 10% being released upon closing of the reverse takeover and the balance as to 15% every six months. Of these shares, as at February 29, 2012, 1,853,724 remain in escrow. The remaining 5,880,614 common shares are subject to resale restrictions over a period of three years, with 10% being free-trading, and the remaining shares subject to resale restrictions, as to 15% becoming free-trading every six months.

#### Performance Shares

There are 10,000,000 performance shares set aside for officers, directors and employees of Stellar CA based on meeting milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of products. During the year ended August 31, 2011, the Company reached the first performance share milestone and issued 3,333,335 shares (issued at a value of \$3,400,000) of the Company to the individuals named in the Performance Share Plan. The issuance of performance shares was recorded as share-based payments.

#### Warrants

A summary of the Company's outstanding warrants is as follows:

	Number of Warrants	Weighted Average Exercise Price
		CDN \$
<b>Balance, as at August 31, 2010</b>	6,959,531	\$ 0.37
Granted	8,268,600	\$ 0.80
Exercised	(2,148,805)	\$ 0.37
<b>Balance, as at August 31, 2011</b>	13,079,326	\$ 0.65
Granted	(2,318,600)	\$ 0.37
Expired	(2,492,126)	\$ 0.40
<b>Balance, as at February 29, 2012</b>	8,268,600	\$ 0.82

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited – Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### 10. Share Capital (continued)

The following table summarizes information about the warrants outstanding as at February 29, 2012:

CDN Exercise	Number of
--------------	-----------



Price	Warrants	Expiry Date	
CDN \$			
\$0.50	1,500,000	March 28, 2012	<i>Subsequently extended to March 28, 2013</i>
\$0.35	210,000	March 28, 2012	<i>Subsequently expired</i>
\$1.15	6,213,000	November 14, 2012	
\$0.60	345,600	November 14, 2012	
8,268,600			

#### Warrant Liability – Warrants Issued With Canadian Dollar Exercise Prices

Equity offerings were completed in previous periods whereby warrants were issued with exercise prices denominated in Canadian dollars. The Company's functional currency is in US dollars. As a result of having exercise prices denominated in other than the Company's functional currency, these warrants meet the definition of derivatives and are therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the Statements of Consolidated Loss. The fair value of the warrants was determined using the Black-Scholes option pricing model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities was reclassified to equity.

The fair value of warrants exercised during the periods ended February 29, 2012 and 2011 was determined using the Black-Scholes option pricing model, using the following assumptions:

	<u>2012</u>	<u>2011</u>
Risk free interest rate	2.49%	3.15%
Expected life (years)	0.11	0.78
Expected share price volatility	110%	104.79%

The fair value of warrants granted was determined using the Black-Scholes option pricing model, using the following weighted average assumptions at the end of each reporting period:

	<u>2012</u>	<u>2011</u>
Risk free interest rate	N/A	1.61%
Expected life (years)	N/A	1.1
Expected share price volatility	N/A	107%
Expected dividend yield	N/A	0%

Option pricing models require the input of highly subjective assumptions regarding volatility. The Company has used historical volatility to estimate the volatility of the share price.

#### Options

The Company has a stock option plan ("the Plan") to be administered by the Board of Directors, which has the discretion to grant options for up to a maximum of 20% of the issued and outstanding share capital amount and subject to a maximum of 8,785,000 shares. The exercise price of an option is subject to a minimum of \$0.10

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### **10. Share Capital (continued)**

#### Options (continued)

per share, not less than the closing price (less applicable discount) on the Exchange on the last trading day preceding the grant date. However, all of the stock options which have been granted are subject to the following vesting schedule:

- (a) One-third shall vest immediately;
- (b) One-third shall vest 12 months from the Effective Date; and
- (c) One-third shall vest 18 months from the Effective Date.

Options have been issued under the Plan allowing the holders to purchase common shares of the Company as follows:

	<u>Number of Options</u>	<u>Weighted Average Exercise Price</u>
<b>Balance, as at August 31, 2010</b>	2,700,000	CDN \$ \$ 0.28

Granted	1,554,600	\$	0.68
<b>Balance, as at August 31, 2011</b>	4,254,600	\$	0.43
Granted	90,000	\$	0.41
Cancelled	(105,000)	\$	0.77
<b>Balance, as at February 29, 2012</b>	4,239,600	\$	0.42

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited – Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### 10. Share Capital (continued)

#### Options (continued)

The following table summarizes information about the options under the Plan outstanding and exercisable as at February 29, 2012:

CDN Exercise Price	Number of Options	Exercisable at February 29, 2012	Expiry Date
\$0.28	2,431,667	2,431,667	April 9, 2017
\$0.25	75,000	75,000	May 17, 2017
\$0.28	70,000	70,000	June 17, 2017
\$0.28	20,000	20,000	June 28, 2017
\$0.28	70,000	70,000	July 13, 2017
\$0.64	70,000	46,667	October 25, 2017
\$1.00	60,000	40,000	February 10, 2018
\$1.00	23,333	23,333	March 8, 2018
\$0.65	1,329,600	443,200	August 8, 2018
\$0.50	5,000	1,667	September 26, 2018
\$0.40	80,000	26,667	December 22, 2018
\$0.42	5,000	1,667	February 16, 2019
	4,239,600	3,249,868	

Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's stock options. The estimated fair value of the stock options granted during the periods ended February 29, 2012 and 2011 was determined using a Black-Scholes option pricing model with the following weighted average assumptions:

	<u>2012</u>	<u>2011</u>
Risk free interest rate	1.51%	2.69%
Expected life (years)	7.0	7.0
Expected share price volatility	141%	110%
Expected dividend yield	0%	0%

The average fair value of stock options awarded during the period was \$0.41 and \$0.87 respectively.

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited – Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### 11. Biological Assets

Changes in biological assets are as follows:

<u>February 29, 2012</u>	February 28, 2011
--------------------------	-------------------

Carrying amount at beginning of period	\$	5,763	\$	3,173
Increases in fair value due to purchases		-		3,685
Changes in fair value due to quantity and price changes		422		(593)
Carrying amount at end of period	\$	6,185	\$	6,265

## 12. Supplemental Disclosure of Non-Cash Transactions

Supplemental disclosure of non-cash financing and investing activities include the following:

	February 29, 2012	February 28, 2011
Financing activities:		
Share issuance costs – agent’s options	\$ -	\$ 276,448
Warrant valuations on private placements	-	3,003,870
Transfer to share capital on exercise of warrants	190,425	1,213,969
Cash paid during the period for taxes	800	5,000
Cash paid during the period for interest	-	-

## 13. Events After the Reporting Period

Subsequent to February 29, 2012, the Company:

- Granted incentive stock options to directors, officers, employees and consultants to purchase 1,279,600 common shares, exercisable at a price of CDN\$0.42 per share, and 50,000 common shares, exercisable at a price of CDN\$0.42 per share for a period of seven years.

## 14. Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

## 15. First Time Adoption of IFRS

As stated in Note 2, these consolidated financial statements are the Company’s second condensed interim consolidated financial statements prepared in accordance with IFRS.

The accounting policies in Note 3 have been applied in preparing the condensed interim consolidated financial statements for the period ended February 29, 2012 and 2011, the financial statements for the year ended August 31, 2011, and the opening IFRS statement of financial position on the Transition Date, September 1, 2010.

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited – Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### 15. First Time Adoption of IFRS (continued)

In preparing the opening IFRS statement of financial position and the financial statements for the interim period ended February 28, 2011 and annual period ended August 31, 2011, the Company has adjusted amounts reported previously in financial statements prepared in accordance with Canadian GAAP. An explanation of how the transition from Canadian GAAP to IFRS has effected the Company’s financial position and financial performance is set out in the following tables.

The guidance for first time adoption of IFRS is set out in IFRS 1. IFRS 1 provides for certain mandatory exceptions and optional exemptions for first time adopters of IFRS. The Company has elected to take the following IFRS 1 optional exemptions:

#### (a) Optional exemptions

##### *Share-based payments*

IFRS 2, Share-based Payments, encourages application of its provisions to equity instruments granted on or before November 7, 2002, but permits the application only to equity instruments granted after November 7, 2002 that were not vested by the Transition Date. The Company elected to take the exemption available under IFRS 1 and applied IFRS 2 for all equity instruments granted after November 7, 2002 that had not vested by the Transition Date.

##### *Financial Instruments: Presentation*

IAS 32, Financial Instruments: Presentation requires an entity to split a compound financial instrument at inception into separate liability and equity components. If the liability component is no longer outstanding, retrospective application of IAS 32 involves separating two portions of equity. The first portion is in retained earnings and represents the cumulative interest accreted on the liability component. The other portion represents the original equity component. However, in accordance with this IFRS, a first-time adopter need not separate these two portions if the liability component is no longer outstanding at the date of transition to IFRS.

(b) Mandatory exceptions

*Estimates*

In accordance with IFRS 1, an entity's estimates under IFRS at the date of IFRS transition must be consistent with estimates made for the same date under previous Canadian GAAP, unless there is objective evidence that those estimates were in error. The Company's IFRS estimates as of September 1, 2010 are consistent with Canadian GAAP estimates for the same date.

*Reconciliation of Canadian GAAP and comprehensive loss to IFRS*

IFRS requires an entity to reconcile equity, comprehensive loss and cash flows for prior periods. The changes made to the statement of financial position and statements of comprehensive loss as shown below have resulted in reclassifications of various amounts on the statements of cash flows, however as there have been no material adjustments to the net cash flows, no reconciliation of the statement of cash flows has been prepared.

**Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

**15. First Time Adoption of IFRS (continued)**

The September 1, 2010 Canadian GAAP balance sheet has been reconciled to IFRS as follows:

Note	September 1, 2010		
	Canadian GAAP	Effect of transition to IFRS	IFRS
<b>Assets:</b>			
Current assets:			
	\$ 2,003,296	\$ -	\$ 2,003,296
	568,495		568,495
	22,940		22,940
	2,594,731	-	2,594,731
Noncurrent assets:			
ii	-	3,173	3,173
	89,577		89,577
	200,000		200,000
	8,766		8,766
	\$ 2,893,074	\$ 3,173	\$ 2,896,247
<b>Liabilities and Shareholders' Equity:</b>			
Current liabilities:			
	\$ 420,610	\$ -	\$ 420,610
Long-term liabilities			
iii	-	797,310	797,310
Shareholders' equity:			
i & iii	2,610,682	(246,428)	2,364,254
i & iii	870,412	(500,974)	369,438
	(1,008,630)	(46,735)	(1,055,365)
	2,472,464	(794,137)	1,678,327
	\$ 2,893,074	\$ 3,173	\$ 2,896,247

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 15. First Time Adoption of IFRS (continued)

The February 28, 2011 Canadian GAAP interim balance sheet has been reconciled to IFRS as follows:

Note	February 28, 2011			
	Canadian GAAP	Effect of transition to IFRS	IFRS	
<b>Assets:</b>				
Current assets:				
	\$	\$	\$	
Cash and cash equivalents	6,014,042	-	6,014,042	
Accounts receivable	22,869		22,869	
Share subscriptions receivable	21,233		21,233	
Prepaid expenses	30,411		30,411	
	<u>6,088,555</u>	<u>-</u>	<u>6,088,555</u>	
Noncurrent assets:				
Biological assets	<i>ii</i>	-	6,265	6,265
Property, plant and equipment		306,176		306,176
Licensing rights		200,000		200,000
Deposits		10,366		10,366
	<u>\$ 6,605,097</u>	<u>\$ 6,265</u>	<u>\$ 6,611,362</u>	
<b>Liabilities and Shareholders' Equity:</b>				
Current liabilities:				
Accounts payable and accrued liabilities	\$	\$	\$	
Deferred revenue	118,843	-	118,843	
	<u>15,150</u>	<u>-</u>	<u>15,150</u>	
	<u>133,993</u>	<u>-</u>	<u>133,993</u>	
Long-term liabilities				
Warrant liability	<i>iii</i>	-	7,349,405	7,349,405
Shareholders' equity:				
Share capital	<i>i &amp; iii</i>	8,862,298	(60,055)	8,802,243
Share-based payment reserve	<i>i &amp; iii</i>	3,284,031	(2,693,934)	590,097
Deficit		(5,675,225)	(4,589,151)	(10,264,376)
		<u>6,471,104</u>	<u>(7,343,140)</u>	<u>(872,036)</u>
	<u>\$ 6,605,097</u>	<u>\$ 6,265</u>	<u>\$ 6,611,362</u>	

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 15. First Time Adoption of IFRS (continued)

The August 31, 2011 Canadian GAAP balance sheet has been reconciled to IFRS as follows:

Note	August 31, 2011		
	Canadian GAAP	Effect of transition to IFRS	IFRS
<b>Assets:</b>			
Current assets:			
	\$	\$	\$
Cash and cash equivalents	4,145,492	-	4,145,492
Accounts receivable	39,021		39,021
Prepaid expenses	36,604		36,604
	<u>4,221,117</u>	<u>-</u>	<u>4,221,117</u>

Noncurrent assets:			
Biological assets	ii	-	5,763
Property, plant and equipment		338,224	338,224
Licensing rights		173,810	173,810
Deposits		17,500	17,500
		<u>\$ 4,750,651</u>	<u>\$ 5,763</u>
			<u>\$ 4,756,414</u>

#### Liabilities and Shareholders' Equity:

Current liabilities:			
Accounts payable and accrued liabilities		\$ 159,137	\$ -
			\$ 159,137
Long-term liabilities			
Warrant liability	iii	-	1,527,374
			<u>1,527,374</u>
Shareholders' equity:			
Share capital	i & iii	9,213,640	55,793
Share-based payment reserve	i & iii	3,472,627	(2,738,103)
Deficit		(8,094,753)	1,160,699
		<u>4,591,514</u>	<u>(1,521,611)</u>
		<u>\$ 4,750,651</u>	<u>\$ 5,763</u>
			<u>\$ 4,756,414</u>

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 15. First Time Adoption of IFRS (continued)

The Canadian GAAP statement of interim comprehensive loss for the three month period ended February 28, 2011 has been reconciled to IFRS as follows:

Note	Three Months Ended February 28, 2011		
	Canadian GAAP	Effect of transition to IFRS	IFRS
<b>Revenues:</b>			
Contract income	\$ 15,000	\$ -	\$ 15,000
Commercial sales	4,200		4,200
Grant revenue	526,217		526,217
	<u>545,417</u>	<u>-</u>	<u>545,417</u>
<b>Costs of Production, Aquaculture and Grants:</b>			
Cost of production and aquaculture	ii	136,268	(11)
Grant costs		33,084	
		<u>169,352</u>	<u>(11)</u>
			<u>169,341</u>
<b>Gross Margin (Loss)</b>		<u>376,065</u>	<u>11</u>
			<u>376,076</u>
<b>Expenses:</b>			
Salaries, wages and benefits		275,115	
Research and development		295,525	
Legal and professional services		63,030	
Share-based payments	i	3,472,946	33,852
General and administration		161,469	
Amortization and depreciation		16,022	
Allocation of expenses to grant costs		(10,632)	
		<u>4,273,475</u>	<u>33,852</u>
			<u>4,307,327</u>
<b>Other Income:</b>			
Change in fair value of warrant liability	iii	-	772,702
Foreign exchange gain (loss)		91,053	
Interest income		3,046	
		<u>94,099</u>	<u>772,702</u>
			<u>866,801</u>
<b>Loss Before Income Tax</b>		<u>(3,803,311)</u>	<u>738,861</u>
Income tax expense		-	
			<u>(3,064,450)</u>
<b>Loss and Comprehensive Loss for the Period</b>		<u>\$ (3,803,311)</u>	<u>\$ 738,861</u>
			<u>\$ (3,064,450)</u>

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 15. First Time Adoption of IFRS (continued)

The Canadian GAAP statement of interim comprehensive loss for the six month period ended February 28, 2011 has been reconciled to IFRS as follows:

	Note	Six Months Ended February 28, 2011		
		Canadian GAAP	Effect of transition to IFRS	IFRS
<b>Revenues:</b>				
Contract income		\$ 30,000	\$ -	\$ 30,000
Commercial sales		9,838		9,838
Grant revenue		575,475		575,475
		615,313	-	615,313
<b>Costs of Production, Aquaculture and Grants:</b>				
Cost of production and aquaculture	ii	253,592	(3,092)	250,500
Grant costs		62,358		62,358
		315,950	(3,092)	312,858
<b>Gross Margin (Loss)</b>		299,363	3,092	302,455
<b>Expenses:</b>				
Salaries, wages and benefits		376,832		376,832
Research and development		578,180		578,180
Legal and professional services		154,071		154,071
Share-based payments	i	3,560,897	59,762	3,620,659
General and administration		296,471		296,471
Amortization and depreciation		29,152		29,152
Allocation of expenses to grant costs		(23,126)		(23,126)
		4,972,477	59,762	5,032,239
<b>Other Income:</b>				
Change in fair value of warrant liability	iii	-	(4,485,746)	(4,485,746)
Foreign exchange gain (loss)		6,511		6,511
Interest income		5,008		5,008
		11,519	(4,485,746)	(4,474,227)
<b>Loss Before Income Tax</b>		(4,461,595)	(4,542,416)	(9,204,011)
Income tax expense		5,000		5,000
<b>Loss and Comprehensive Loss for the Period</b>		\$ (4,666,595)	\$ (4,542,416)	\$ (9,209,011)

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

(in US Dollars)

### 15. First Time Adoption of IFRS (continued)

The Canadian GAAP statement of comprehensive loss for the year ended August 31, 2011 has been reconciled to IFRS as follows:

	Note	August 31, 2011		
		Canadian GAAP	Effect of transition to IFRS	IFRS
<b>Revenues:</b>				
Contract income		\$ 60,000	\$ -	\$ 60,000
Commercial sales		18,988		18,988
Grant revenue		618,199		618,199

		697,187	-	697,187
<b>Costs of Production, Aquaculture and Grants:</b>				
Cost of production and aquaculture	ii	413,397	(2,590)	410,807
Grant costs		595,686		595,686
		<u>1,009,083</u>	<u>(2,590)</u>	<u>1,006,493</u>
<b>Gross Margin (Loss)</b>		<u>(311,896)</u>	<u>2,590</u>	<u>(309,306)</u>
<b>Expenses:</b>				
Salaries, wages and benefits		797,263		797,263
Research and development		906,518		906,518
Legal and professional services		283,122		283,122
Share-based payments	i	4,007,116	15,593	4,022,709
General and administration		747,883		747,883
Amortization and depreciation		87,325		87,325
Allocation of expenses to grant costs		(41,170)		(41,170)
		<u>6,788,057</u>	<u>15,593</u>	<u>6,803,650</u>
<b>Other Income:</b>				
Foreign exchange gain (loss)		3,333		3,333
Change in fair value of warrant liability	iii	-	1,220,437	1,220,437
Interest income		11,297		11,297
		<u>14,630</u>	<u>1,220,437</u>	<u>1,235,067</u>
<b>Loss Before Income Tax</b>		<u>(7,085,323)</u>	<u>1,207,434</u>	<u>(5,877,889)</u>
Income tax expense		800		800
<b>Loss and Comprehensive Loss for the Period</b>		<u><u>\$(7,086,123)</u></u>	<u><u>\$ 1,207,434</u></u>	<u><u>\$ (5,878,689)</u></u>

## Stellar Biotechnologies, Inc

Notes to Consolidated Interim Consolidated Financial Statements  
(Unaudited – Prepared by Management)  
For the Six Months Ended February 29, 2012  
(in US Dollars)

### 15. First Time Adoption of IFRS (continued)

Explanations for the adjustments are as follows:

#### (i) Share-based payments

IFRS 2 is effective for the Company as at September 1, 2010 and is applicable to:

- New grants for share-based payments subsequent to September 1, 2010
- Equity-settle share-based compensation awards granted subsequent to November 7, 2002 and that vest after September 1, 2010; and
- Awards that are modified on or after September 1, 2010, even if the original grant of the award was not accounted for in accordance with IFRS 2.

Canadian GAAP allows the Company to calculate the fair value of the share-based compensation on all awards granted and recognizes the expense from the date of grant over the vesting period using the straight-line methodology. The Company determines the fair value of share options granted using the Black-Scholes option pricing model.

IFRS 2 requires each tranche in an award with graded vesting features to be treated as a separate grant with a different vesting date and fair value. Each grant is accounted for on that basis.

As a result, share-based payment reserves was increased by \$29,216 at September 1, 2010 (February 28, 2011 - \$88,978; August 31, 2011 - \$44,809) and deficit has been increased by \$29,216 at September 1, 2010 (February 28, 2011 - \$88,978; August 31, 2011 - \$44,809). The impact on loss and comprehensive loss for the period ended February 28, 2011 was an increase of share-based payments of \$59,762 (year ended August 31, 2011 - \$15,593).

#### (ii) Biological assets

IFRS 41 is effective for the Company as at September 1, 2010. Biological assets are living plants or animals including those which can provide agricultural produce. The Company's keyhole limpet colonies are bearer assets from which KLH is harvested.



Under IFRS, the biological assets are recorded at fair value less costs to sell, measured upon initial recognition and at the end of each reporting period. Accordingly, biological assets increased by \$3,173 at September 1, 2010 (February 28, 2011 - \$6,265; August 31, 2011 - \$5,763). The impact on loss and comprehensive loss for the period ended February 28, 2011 was \$3,092 (year ended August 31, 2011 - \$2,590).

*(iii)Warrant Liability*

Under IFRS, the warrants issued by the Company with an exercise price denominated in a currency other than its functional currency must be classified as liabilities (as they do not meet the definition of an equity instrument) and are recognized at fair value with changes in fair value being recognized as a profit or loss. There is no such requirement under Canadian GAAP as warrants issued by the Company meet the definition of an equity instrument. The Company's outstanding warrants are denominated in Canadian dollars and the functional currency is the US dollar therefore the Company will recognize the warrants as a liability with changes to the fair value of the liability being recognized in the Statements of Consolidated Loss.

## **Stellar Biotechnologies, Inc**

Notes to Consolidated Interim Consolidated Financial Statements

(Unaudited – Prepared by Management)

For the Six Months Ended February 29, 2012

*(in US Dollars)*

### **15. First Time Adoption of IFRS (continued)**

*(iii)Warrant Liability (continued)*

As a result, warrant liability increased by \$797,310 at September 1, 2010 (February 28, 2011 - \$7,349,405; August 31, 2011 - \$1,527,374). The impact on loss and comprehensive loss for the period ended February 28, 2011 was a gain of \$4,485,746 (year ended August 31, 2011 - \$1,220,437).

### **16. Loss Recovery**

A shipment of KLH was damaged by a vendor. The vendor agreed to reimburse the Company for the value of the KLH. In accordance with IAS 37, *Provisions, Contingent Liabilities and Contingent Assets*, the loss recovery was recorded during the period ended February 29, 2012 when the realization of income was virtually certain.



**Management Discussion and  
Analysis**

**For the Six Months Ended February 29, 2012  
As at April 30, 2012**

## Introduction

The following Management Discussion and Analysis (“MD&A”) of Stellar Biotechnologies, Inc. (the “Company” or “Stellar”) has been prepared by management, in accordance with the requirements of National Instrument 51-102 *Continuous Disclosure Obligations* as of April 30, 2012 and should be read in conjunction with the unaudited condensed interim consolidated financial statements for the six months ended February 29, 2012 and 2011 and the related notes contained therein which have been prepared under International Financial Reporting Standards (“IFRS”). The following should also be read in conjunction with the audited financial statements and the related MD&A for the year ended August 31, 2011, and all other disclosure documents of the Company. It should be noted that the audited financial statements for the year ended August 31, 2011 were prepared in accordance with Canadian Generally Accepted Accounting Principles (“Canadian GAAP”). The information contained herein is not a substitute for detailed investigation or analysis on any particular issue. The information provided in this document is not intended to be a comprehensive review of all matters and developments concerning the Company. The Company is presently a “Venture Issuer” as defined in NI 51-102. Additional information relevant to the Company’s activities can be found on SEDAR at [www.sedar.com](http://www.sedar.com) and the Company’s website at [www.stellarbiotechnologies.com](http://www.stellarbiotechnologies.com)

All financial information in this MD&A related to 2011 and 2010 has been prepared in accordance with IFRS and all dollar amounts are quoted in US dollars, the presentation currency of the Company, unless specifically noted.

To the extent that any statements made in this document contain information that is not historical, these statements are considered forward-looking and are subject to risks and uncertainties. Actual results, levels of activities, performance, or achievements could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of research and clinical trials, the uncertainties related to the regulatory process, and the commercialization of the Company’s products thereafter.

The cautionary statements made in this report should be read as applying to forward-looking statements wherever they appear in this report. The Company’s future results could differ materially from those discussed here. Factors that could cause or contribute to these differences include those discussed under “Risks and Uncertainties”.

## Description of Corporate Entity

Stellar Biotechnologies, Inc. (“the Company” or “Stellar”, formerly CAG Capital Inc.) is listed on the TSX Venture Exchange (“the Exchange”) as a Tier 2 issuer under the trading symbol KLH since April 19, 2010 (formerly under CAG.P). The Company’s head office is located in Port Hueneme, California, USA.

Stellar is a company with biotech and pharmaceutical customers and research partners, \$6 million in research having been conducted with US government National Institutes of Health (“NIH”) and National Science Foundation (“NSF”) grants, with a portfolio of intellectual property involving new aquaculture and marine culture processes as well as technology for producing pharmaceutical formulations of Keyhole Limpet Hemocyanin (“KLH”) that sell for \$5,000 - \$200,000 per gram into the medical, academic and research markets. KLH is an essential component for many cancer vaccines and highly anticipated [therapeutic vaccines](#), including those for lymphoma, sarcoma, small cell lung cancer, Alzheimer’s disease, rheumatoid arthritis, lupus, and Post Traumatic Stress Disorder chemical dependencies.

## Global Overview of KLH

The Company’s core activity is production of purified KLH for use in a new class of medicines known as therapeutic vaccines and in immunological research. The Company is the only company dedicated solely to developing and commercializing KLH. Demand for its KLH is driven by over a dozen biopharmaceutical companies that have advanced KLH-based therapeutic vaccines in clinical trials for a wide variety of serious chronic diseases.

KLH is a potent immunogenic (i.e. a substance that induces an immune response) high-molecular-weight protein. It offers an ideal carrier molecule for vaccine antigens (i.e., substances that promote the generation of antibodies) against cancers and infectious agents. The combination of an antigen against specific tumor cell-types, conjugated to the Immunogenic (“IMG”) KLH molecule, is the basis for a proven strategy for a new class of drugs known as therapeutic vaccines. Potent yet proven safe in humans, KLH is highly prized as a critical component of several important therapeutic vaccines including vaccines for lymphoma, bladder, breast, colon, and other cancers.

The Company is positioned to become the premier worldwide supplier of vaccine-grade KLH. The commercial prospects of KLH vaccines under development are threatened by one common factor; reliance on KLH from a fragile wild population of *M. crenulata*, which is found only sporadically in the coastal waters from central California to northern Baja California, Mexico. There is currently no regulated fishery to protect this limited population from over-exploitation and fishery stocks are being rapidly depleted before a bona fide regulated commercial fishery can be instituted to mitigate the unsustainable harvesting pressure. With the expected imminent potential approval of KLH-based vaccines, the limited natural population of *M. crenulata* will not sustain KLH supplies. We believe that the Company is the only company that has aquaculture and harvesting technology to ensure sustainable supplies.

The Company has developed what is believed to be the world’s only dedicated aquaculture technology and captive, hatchery-reared populations of *M. crenulata* for sustainable vaccine-grade KLH production. The Company’s intellectual properties include sophisticated proprietary aquaculture methods, the only patented non-lethal hemolymph extraction process, and proprietary vaccine-grade protein purification methods for production of KLH that meets the specific needs of vaccine developers.

Currently, the Company provides cGMP (current good manufacturing practices) KLH products to the biopharmaceutical and vaccine development markets, with KLH supply contracts in place with two vaccine developers, including one of the world’s largest pharmaceutical companies, and it expects to complete contract negotiations with additional customers in the future.

## Company’s Technology

The Company’s proprietary intellectual property includes patent, patent pending and key trade secrets related to sourcing and purifying KLH for medical markets by spawning and maintaining the rare [keyhole limpet](#) which is found only in the slender strip of ocean off the coast of northern Baja to central California; non-lethal hemolymph extraction technology for environmentally sustainable production of KLH and

highly efficient manufacturing methods for the purification of various formulations of the KLH molecule for use in dynamic pharmaceutical and veterinary markets as a powerful immune stimulant and vaccine carrier protein with a long history of efficacy, safety and low toxicity.

## **Key Employees**

**Frank R. Oakes** is President, Chief Executive Officer, and Director. Mr. Oakes has 30 years of management experience in aquaculture including a decade as CEO of The Abalone Farm, Inc., during which he led that company through the R&D, capitalization, and commercialization phases of development to become the first profitable and largest abalone producer in the U.S. He is the inventor of the company's patented method for non-lethal extraction of hemolymph from the keyhole limpet. He is the Principal Investigator ("PI") on the company's current Small Business Innovation Research ("SBIR") grant from the National Science Foundation and was PI on the company's Phase I and II SBIR grants from the NIH's Centre for Research Resources, and a California Technology Investment Partnership ("CalTIP") grant from the Department of Commerce. He has consulted and lectured for the aquaculture industry around the world. Frank received his Bachelor of Science degree from California State Polytechnic University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance ("LARTA") University's management-training program.

**Scott Davis** is Chief Financial Officer. He is a partner of Cross Davis & Company LLP Certified General Accountants, a firm focused on providing accounting and management services for publicly-listed companies. His experience includes CFO positions of several companies listed on the TSX Venture Exchange, and his past experience consists of senior management positions, including three years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davidson & Company LLP Chartered Accountants as an Auditor, five years with Pacific Opportunity Capital Ltd. as an Accounting Manager, and two years at Jacobson Soda and Hosak, Chartered Accountants.

**Darrell Brookstein** is Executive Vice President, Corporate Development & Finance, Corporate Secretary and Director. He was Managing Director of The Nanotech Company, LLC. He has founded and been CEO of multiple investment firms in diverse fields and has published books and newsletters on investing in cutting-edge technology and natural resource finance. He is a graduate of Duke University.

**Herbert S. Chow, Ph.D.** is Vice President - Product Development. Dr. Chow has held key business management and product development positions in new biologic devices, clinical diagnostic and consumer diagnostic markets. He held key senior management positions with start-up biotechnology companies, as well as international pharmaceutical companies Abbott Labs and Johnson & Johnson. Dr. Chow earned his BS in Microbiology and Immunochemistry at Ohio State University and his Ph.D. in Immunopathology at the University of Illinois.

**John S. Sundsmo, Ph.D.** is Vice President, Research & IP Management. He has had leadership positions in biopharmaceutical companies including Collagen Corporation, Triton Biosciences/Royal Dutch Shell, Viagene, International Medical Innovations, TransCell Therapeutics and PrimeGen Biotech. He was an Intellectual Property attorney with Christensen, O'Connor (Seattle) and Weiss, Jensen (Seattle/Portland). He earned his Ph.D. in Microbiology/Immunology at the University of Washington.

**Catherine Brisson, Ph.D.** is Director of Quality Assurance & Regulatory Affairs. Dr. Brisson has extensive experience in the biotech, pharmaceutical and medical device arenas with cross-functional expertise in Quality Assurance and Regulatory Affairs providing leadership and direction over cGMP, GLP & GCP operations in a clinical development and commercial setting. She has held key positions in Quality Control, Validation and Product/Process Development areas with start-up biotechnology companies, as well as an international pharmaceutical company, Sicor Pharmaceuticals, Inc. Dr. Brisson earned her BS in Chemistry at North Carolina State University and her Ph.D. in Organic Chemistry at the University of North Carolina.

## **Corporate Goals and Objectives**

The Company's goal is to execute its business strategy:

1. Produce, maintain and develop keyhole limpets through key intellectual property ("IP").
2. Continuously advance key IP to extract, purify and formulate KLH profitably, while increasing the number and maintaining the good health of the essential source animals.
3. Market and sell the Company's formulations of KLH and use consistent efforts to expand markets, promote the use of KLH within the academic, research, pharmaceutical, biotech and medical diagnostic markets.
4. Alone and in partnership with others, develop and sell as many proprietary KLH-based products as possible for the medical diagnostic and therapeutic markets.

Since our report in November 2011, Stellar has continued to make significant progress on many important fronts and continues to advance our corporate mandate and achieve goals for long-term shareholder benefit.

## **Grants and Non-Dilutive Funding**

We remain active in the pursuit of opportunities through grant programs that offer non-dilutive funding for research and business development for projects that align directly with the Company's strategic pathway. In December 2010, the Company announced a \$99K award from the National Science Foundation through the prestigious Technology Enhancement for Commercial Partnerships ("TECP") program. This grant was further expanded in August 2011 through a \$499K Phase IIB supplement award from NSF to continue funding for Stellar's SBIR research for two additional years. These awards increased the total NSF SBIR grant funding for Aquaculture technology development to a total of more than \$1,000,000.

## **Corporate Milestones**

The Company continues to make progress on the final two of three milestones disclosed in our Qualifying Transaction documents in 2010. We expect to announce positive results on achieving both goals in 2012. Stellar has also moved quickly to develop its suite of diagnostic products and in April 2012 we announced the launch of the first suite of 6 preclinical ELISA (enzyme-linked immunosorbent assays) test kits targeted for the immunotoxicity drug development markets.

## ***Business Development***

In December 2010, we announced the exclusive in-licensing of Bayer intellectual property we developed jointly with Bayer Innovation GmbH (“BIG” or “Bayer”) as an outgrowth of our previous joint development agreement. In May 2011 we met with Bayer and another company in Germany to explore opportunities to broaden the relationship to include possible future products. During the second quarter of fiscal year 2012, we completed a successful cGMP manufactured lot of KLH20-MV using the method jointly developed under the collaborative agreement. The Company is planning to amend its DMF to reflect the optimized manufacturing method.

In May 2011 Stellar entered into an agreement for marketing and sales with SAFC®, a business unit of Sigma-Aldrich (NASDAQ: SIAL) a global leader in biopharmaceutical contract manufacturing. Under the agreement, Stellar will produce KLH commercial intermediate and SAFC will sell, distribute and market cGMP-grade HMW KLH (high molecular weight keyhole limpet hemocyanin) that uses only Stellar aquaculture-derived KLH for applications in therapeutic vaccines

This collaboration is expected to increase access to a scalable source for KLH, a critical immunostimulatory vaccine carrier protein that will enable the transition from clinical research to commercialization of conjugate vaccine platforms, while managing costs and the risk of supply constraints faced by suppliers that rely on the exploitation of the critically limited natural resource. In September 2011, we announced that the Company received the first purchase order for KLH under this agreement, for a low six figure US\$ amount.

With guidance received during its first Pre-Investigational Device Exemption (“Pre-IDE”) meeting with the U.S. Food and Drug Administration (“FDA”) in May 2011, Stellar is continuing the pre-clinical testing of its KLH products to develop the essential safety and efficacy data needed to execute the Company’s regulatory strategy for approval of its diagnostic product for human use. If approved in the future, this product platform has the potential to dramatically increase the use of Stellar KLH.

During October 2011, Stellar entered into an exclusive manufacturing and supply agreement with Life Diagnostics ([www.lifediagnosics.com](http://www.lifediagnosics.com)). Life Diagnostics is a leader in the manufacture and sale of ELISA kits, purified biomarkers and antibodies for cardiovascular, inflammation, immunotoxicity and immunology research. Under the agreement, Life Diagnostics will utilize Stellar’s high-quality KLH to develop and manufacture Stellar brand KLH ELISA test kits for the detection of anti-KLH antibodies, for use in the growing immunotoxicity and immunology research markets.

This collaboration is expected to meet the increasing need among pharmaceutical researchers for improved test sensitivity, product consistency and analytical performance. Stellar will supply all aquaculture-derived KLH required for production of the ELISA test kits. Life Diagnostics will manufacture the ELISA test kits, and will work closely with Stellar in the commercial marketing and sale of these products. Initially, the agreement covers six different Stellar KLH ELISA products. The launch of Stellar KLHTM ELISA Test Kits occurred in April 2012.

In April 2012 The Company announced that it had entered into an agreement with the University of Guelph (Ontario, Canada) under which the University has granted Stellar an exclusive option to license a patent pending technology for the development of a vaccine candidate against *Clostridium difficile* infection (“CDI”). *Clostridium difficile* is a major and growing cause of mortality and morbidity in hospitalized patients. CDI-related treatments in the U.S. and European countries are estimated at more than \$7 billion a year. This agreement accentuates Stellar’s commitment to a strategy of acquiring promising vaccine candidates as well as other infectious disease targets that may work synergistically with Stellar’s KLH platform, and have potential to address serious, unmet global clinical needs.

### ***Team and Physical Plant Additions/Changes***

To meet corporate objectives, Stellar has grown dramatically. From 6 employees in April 2010, to a dozen by the end of 2010; we are now a dedicated team of 18 and occupy an additional 4,000 sq. ft. of corporate space 600 yards from the gate to our aquaculture and lab facilities on our government-secured harbour facility, as well as additional lab and clean-room manufacturing space.

### ***U.S. Stock Listing and Shareholders Rights Plan***

The Company filed a draft Form 20-F registration statement application with the SEC during February 2012 as the first step toward registration of its shares in the United States. Once the Form 20-F becomes effective with the SEC, the Company will become a fully reporting issuer in the United States. It will also allow the Company to consider the advantages of listing on one of the US exchanges.

During February 2012, the Company was listed on the Frankfurt Stock Exchange (FSE) as a way to broaden our shareholder base and awareness in Germany and Europe.

The Company adopted a Shareholder Rights Plan effective December 13, 2011, which was ratified and approved by shareholders at its Annual General Meeting held in January 2012.

### ***Aquaculture***

In 2011 the Company completed expansion of its hatchery facility for production on keyhole limpet larvae at its Port Hueneme facility, and has implemented production of limpets at a scale suitable to support multiple culture sites. The Company completed negotiation of a term sheet with a regional aquaculture producer for additional culture capacity to accommodate the increase in hatchery production and to geographically diversify some of the keyhole limpet population. The Company is now conducting the studies required by the California Department of Fish and Game (“CDFG”) to certify the Port Hueneme hatchery facility for transport and stocking of limpets throughout the state of California. It is expected that this will expand our competitive advantage in this field, with newly implemented technologically developed under our NSF grant for the production of limpets in numbers far beyond what we believe could be available from any other source. We remain confident that we have the only renewable, sustainable, aquaculture-based supply source for the important immunogenic protein carrier, cGMP-grade KLH, and are unaware of any other company with the licenses permits, facilities or intellectual property to compete with us in this arena.

### ***Corporate Development***

We have made changes in the board of directors and at the CFO position that were anticipated as a part of the transition from a private company to a public company. The important, one-year transitional positions for which the director and CFO signed on originally were filled by strategically selected team members. Our website has also changed significantly to reflect our evolving market focus. We encourage you to visit our site and sign up to be on our list to receive regular updates by visiting [http://www.stellarbiotechnologies.com/contact/request\\_info/](http://www.stellarbiotechnologies.com/contact/request_info/).

The Stellar team looks forward to the future with great enthusiasm and the expectation that we will continue to achieve the corporate goals and business objectives that bring value to the Company and to serve the interests of our shareholders, partners, customers and employees.

As described below, the Company has continued to make significant progress towards the business objectives and product development milestones defined in the filing Statement issued in respect to the Qualifying Transaction.

Fiscal 2011-12 Objectives	Status
Improve strength of regulatory filings to provide customer support	The Company updated its Drug Master File ("DMF") with the FDA and on May 10, 2011 held a Pre-IDE meeting with FDA's Office of In Vitro Diagnostic Device Evaluation and Safety.
Complete development agreement objectives for process optimization for Subunit product KLH 20M	The Company met this objective and has acquired worldwide rights to the optimized method and successfully transferred the method to its contract manufacturer.
Complete process development for new product IMG KLH (now assigned Product Code KLH-01HV)	In the first quarter of the 2012 fiscal year the Company completed transfer of its manufacturing methods and produced its first lot of cGMP grade KLH-01HV, completing this corporate milestone.
Initiate Preclinical testing of IMG KLH (now assigned Product Code KLH-01HV)	Preclinical testing of the IMG KLH formulation was initiated in September 2011 and the first studies were completed in November 2011 with positive results. Preclinical testing needed to support regulatory filings continues. A Drug Master File with the FDA for this product will be sought during 2012.
Continue strengthening of aquaculture Intellectual Property	In December 2011 the company announced completion of the expansion of its hatchery facility in Port Hueneme, CA in anticipation of increases in demand for its keyhole limpet hemocyanin (KLH) products. This expansion will increase the Stellar's future KLH production capacity to in excess of 20,000 grams of KLH annually. Stellar estimates total current worldwide KLH usage at approximately 2,000 grams per year.

- a) On September 12, 2011, the Company announced an agreement for strategic business planning advisory services with LifeTech Capital, including issues related to input on market landscape, as well as strategic business and product planning.
- b) On September 20, 2011, the Company announced the first purchase order from Sigma-Aldrich under terms of the marketing and sales agreement between the Company and Sigma-Aldrich's SAFC division.
- c) On September 26, 2011, the Company announced that ongoing discussions with a major biotechnologies company have advanced to the negotiation of a Material Transfer Agreement for use of the Company's KLH in joint research into the functional characterization of various preparations of KLH.
- d) On September 26, 2011, the Company announced it granted 5000 stock options exercisable at CDN\$0.50 for a period of seven years under the Company's Share Option Plan.
- e) On October 26, 2011, the Company announced an exclusive manufacturing and supply agreement with Life Diagnostics, a leader in manufacture and sale of ELISA kits. Under the agreement, Life Diagnostics will utilize the Company's high-quality KLH to develop and manufacture KLH ELISA test kits for the detection of anti-KLH antibodies, for use in the growing immunotoxicity and immunology research markets.
- f) On November 2, 2011, the Company announced plans to file Form 20-F registration statement with the SEC as first step to expose US stockbrokers to the Company. A draft Form 20-F registration statement application was filed with the SEC during February 2012. Once the Form 20-F becomes effective with the SEC, the Company will become a fully reporting issuer in the United States. It will also allow the Company to consider the advantages of listing on one of the US exchanges.
- g) On December 6, 2011, the Company announced completion of a major expansion of its keyhole limpet hatchery facility in anticipation of increases in demand for KLH products.
- h) On December 22, 2011, the Company announced it granted 80,000 stock options exercisable at CDN\$0.40 for a period of seven years under the Company's Share Option Plan.
- i) On January 18, 2012, the Company announced that it has retained TheBiotechPanel, Inc., a Florida-based company specializing in financial and investor relations and communications focused on Europe, to provide the Company with investor relation services. TheBiotechPanel, Inc. will assist the Company in fostering productive, continuing dialogues with analysts, brokers, investors and other financial professionals.
- j) On February 16, 2012, the Company announced it granted 5,000 stock options exercisable at CDN\$0.42 for a period of seven years under the Company's Share Option Plan.
- k)



On February 28, 2012, the Company announced that it was recently listed on the Frankfurt Stock Exchange (FSE), and will trade under the symbol RBT.F (WKN A1C5EH).

- l) On March 16, 2012, the Company announced that due to unforeseen personal and business circumstances in Europe, The Biotech Panel, Inc. is not able to provide IR/PR services for the Company and the companies have severed their relationship amicably.
- m) On March 16, 2012, the Company announced that it has received approval from the TSX Venture Exchange to amend the terms of 1,500,000 share purchase warrants by extending the expiry date of the warrants by twelve months from March 28, 2012 to March 28, 2013.
- n) On April 3, 2012, the Company announced the launch of Stellar KLHTM ELISA Test Kits. These new assay kits are designed for the rapid, quantitative measure of anti-KLH antibodies in serum or plasma samples. The Company's product launch includes six different kits to measure either IgG or IgM antibodies in a range of preclinical models.
- o) On April 10, 2012, the Company announced that it has entered into an agreement with the University of Guelph (Ontario, Canada) for the exclusive option to license technology for the development of a vaccine candidate against Clostridium difficile infection ("CDI"). CDI is a major and growing cause of mortality and morbidity in hospitalized patients.
- p) On April 13, 2012, the Company announced it granted 1,279,600 stock options exercisable at CDN\$0.42 for a period of seven years under the Company's Share Option Plan.
- q) On April 25, 2012, the Company announced the launch of KLH Site™ at [www.klhsite.com](http://www.klhsite.com), the first web site dedicated to scientific and clinical information on the use of Keyhole Limpet Hemocyanin protein. KLH Siterm, sponsored by the Company, is a knowledge base that provides KLH information from around the world, in one convenient place. KLH siterm offers links to biomedical literature and clinical studies, news of KLH-enhanced vaccine development, and useful information on KLH biochemistry and manufacture.
- r) On April 26, 2012, the Company announced it granted 50,000 stock options exercisable at CDN\$0.42 for a period of seven years under the Company's Share Option Plan.

## Liquidity and Capital Resources

The Company has incurred significant losses and has an accumulated deficit of \$8,457,015 as at February 29, 2012 (August 31, 2011 - \$6,934,054; September 1, 2010 - \$1,055,365).

The Company had a cash position on February 29, 2012 of \$2,945,496 (August 31, 2011 - \$4,145,492; September 1, 2010 - \$2,003,296) and working capital of \$2,674,780 (August 31, 2011 - \$4,061,980; September 1, 2010 - \$2,174,121).

During the period ended February 29, 2012, the Company issued 2,318,600 shares upon the exercise of warrants for gross proceeds of \$830,715.

In the past the Company has financed its cash requirements primarily through a combination of commercial sales, contract income, grant revenues and equity private placements.

The Company expects to finance its future expenditures through revenues from commercial sales, contract income, grant revenues, by receiving certain milestone payments from its joint development agreement, and by using cash from private placements. The Company is confident that it will achieve these milestones and revenues, however, these events are dependent upon certain factors outside of the Company's control. If not achieved, the Company may be required to obtain additional financing or curtail its development activities and operations.

## Results of Operations

### *For the Six Months Ended February 29, 2012*

The Company had a net loss of \$1,522,961 for the six months ended February 29, 2012 as compared to a net loss of \$9,209,011 for February 28, 2011. This was a decrease in loss of \$7,686,050 over the prior year which can be mainly attributed to:

- Commercial sales of \$113,925 (2011 - \$9,838) due to a large sale of KLH during the period ended February 29, 2012.
- Grant revenue of \$49,682 (2011 - \$575,475) due to non-recurring IRS grants during the period ended February 28, 2011.
- Costs of production and aquaculture of \$324,133 (2011 - \$250,500) due to production costs of new subunit KLH product that is not yet saleable and costs related to expansion of limpet colonies.
- Salaries, wages and benefits of \$533,563 (2011 - \$376,832) due to an increase in the number of employees and salary increases consistent with the Board's compensation policy in order to have appropriate staffing to work toward Company goals.
- Research and development of \$956,409 (2011 - \$578,180) due to increase in R&D activities to work toward Company goals.
- Share-based payments of \$237,916 (2011 - \$3,620,659) The Company granted 90,000 (2011 - 155,000) stock options using the Black-Scholes option pricing model. Share based payments are recognized over the vesting periods using graded vesting. During the six months ended February 28, 2011 the Company issued 3,333,335 shares (issued at a value of \$3,400,000) of the Company to the individuals named in the Performance Share Plan for reaching its first performance share milestone.
- Loss recovery of \$105,000 (2011 - \$Nil) due to recovery of the value of KLH which had been damaged by vendor.
- Change in fair value of warrant liability of \$975,152 (2011 - (\$4,485,746)) due to fluctuations in fair value based on Black-Scholes option pricing model. There were greater differences between the share price and exercise price of warrants as at February 28, 2011 than 2012. Greater differences cause the fair value of the warrant liability to increase. Additionally, more of the warrants have been exercised or expired as at February 29, 2012 than 2011.

The Company had a net loss of \$844,709 for the three months ended February 29, 2012 as compared to a net loss of \$3,064,450 for February 28, 2011. This was a decrease in loss of \$2,219,741 over the prior year which can be mainly attributed to:

- Grant revenue of \$29,665 (2011 - \$526,217) due to non-recurring IRS grants during the period ended February 28, 2011.
- Research and development of \$388,794 (2011 - \$295,525) due to increase in R&D activities to work toward Company goals.
- Share-based payments of (\$39,802) (2011 - \$3,506,798) The Company granted 85,000 (2011 - 85,000) stock options using the Black-Scholes option pricing model. Share based payments are recognized over the vesting periods using graded vesting. During the three months ended February 28, 2011 the Company issued 3,333,335 shares (issued at a value of \$3,400,000) of the Company to the individuals named in the Performance Share Plan for reaching its first performance share milestone.
- Change in fair value of warrant liability of \$261,217 (2011 – \$772,702) due to fluctuations in fair value based on Black-Scholes option pricing model. There were greater differences between the share price and exercise price of warrants as at February 28, 2011 than 2012. Greater differences cause the fair value of the warrant liability to increase. Additionally, more of the warrants have been exercised or expired as at February 29, 2012 than 2011.

### Summary of Quarterly Results

The table below presents selected financial data for the Company's most recently completed quarters. (In \$000's except per share data)

	For the Years Ended August 31,							
	2012		2011				2010	
	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3
	IFRS*		IFRS*		IFRS*		Canadian GAAP	Canadian GAAP
<b>Financial results</b>								
Revenues	\$ 58	\$ 135	\$ 40	\$ 42	\$ 545	\$ 70	\$ 545	\$ 161
Net income (loss) for period	(845)	(678)	738	2,592	(3,064)	(6,145)	295	(793)
Income (loss) per share	(0.02)	(0.02)	0.02	0.06	(0.08)	(0.20)	(0.04)	(0.06)
<b>Balance sheet data</b>								
Cash and cash equivalents	2,945	4,075	4,145	5,099	6,014	6,451	2,003	2,658
Assets	3,478	4,830	4,757	5,715	6,611	7,016	2,893	2,791
Shareholders' equity	2,806	3,691	3,070	2,251	(872)	(2,142)	2,472	2,677

\* These amounts have not been audited. Please refer to Note 15 in the unaudited condensed interim consolidated financial statements for the six-month period ended February 29, 2012 for a reconciliation of Canadian GAAP to IFRS.

### Transactions with Related Parties

For the period ended February 29, 2012, the Company had the following transactions with related parties:

	Salary and Benefits	Consulting	Director Fees	Professional Fees	Accounts Payable
Frank Oakes - Director & Officer	\$ 134,330	\$ -	\$ 4,750	\$ -	\$ -
Dorothy Oakes - Relative of Director & Officer	55,464				
Darrell Brookstein - Director & Officer	151,964		2,500		329
Daniel Morse - Director & Officer	16,667	22,750	2,000		7,500
Malcolm Gefter - Director		6,000	2,000		
David Hill - Director			5,000		
Harvey Wright - Former Director			350		
Scott Davis - Officer				35,058	
	<u>\$ 358,425</u>	<u>\$ 28,750</u>	<u>\$ 16,600</u>	<u>\$ 35,058</u>	<u>\$ 7,829</u>

For the period ended February 28, 2011, the Company had the following transactions with related parties:

	Salary and Benefits	Consulting	Director Fees	Professional Fees	Accounts Payable
Frank Oakes - Director & Officer	\$ 152,650	\$ -	\$ -	\$ -	\$ -
Dorothy Oakes - Relative of Director & Officer	33,376				
Darrell Brookstein - Director & Officer	121,688				
Daniel Morse - Director & Officer	25,000	17,750			
Malcolm Gefter - Director		7,160	2,000		
Kerry Beamish - Former Officer				10,500	
	<u>\$ 332,714</u>	<u>\$ 24,910</u>	<u>\$ 2,000</u>	<u>\$ 10,500</u>	<u>\$ -</u>

The share-based payments to directors, family members of directors and officers of the Company during the six months ended February 29, 2012 was \$140,346 (2011 - \$149,999). Share-based payments are the fair value of the options granted.

On August 14, 2002, the Company entered into an agreement to pay royalties to an officer in exchange for assignment of patent rights to the Company. The royalty is 5% of gross receipts in excess of \$500,000 annually from products using this invention. The Company's current operations utilize this invention. The royalties for the period ending February 29, 2012 were \$Nil (2011 - \$Nil).

### Commitments

The Company leases three buildings and facilities under sublease agreements with the Port Hueneme Surplus Property Authority. On September 1, 2010, the Company exercised its option to extend the three buildings and facilities sublease agreements. The monthly



base rents total \$7,071 effective November 1, 2010, for a term of 5 years with rents adjusted by the CPI index every November 1st.

The Company also leases office facilities effective July 1, 2011 to June 30, 2014. Rent is \$5,126 per month with 3% cost of living increases each year.

Future minimum lease payments as at February 29, 2012 are as follows:

	<b>February 29, 2012</b>	<b>August 31, 2011</b>
<b>For The Year Ending August 31,</b>		
2012	\$ 73,492	\$ 146,676
2013	148,531	148,531
2014	139,328	139,328
2015	84,852	84,852
2016	14,142	14,142
	<b>\$ 460,345</b>	<b>\$ 533,529</b>

Rent expense on these lease agreements for the six months ended February 29, 2012 was \$85,231 (2011 - \$49,200).

The Company has purchase order commitments totalling approximately \$89,000 at February 29, 2012, for contract manufacturing organizations and consultants (August 31, 2011 - \$184,000; September 1, 2010 - \$117,000).

The Company has commitments under certain supply agreements with customers for fixed prices per gram on a nonexclusive basis except within that customer's field of use.

### **Investor Relations**

In addition to internal investor relations and corporate development personnel, the Company contracted the services of an investor relations firm, Maximus Strategic Consulting Inc., through September 2011 in order to increase exposure to North American and European retail brokers, institutions and investors. Beginning in January 2012, the Company contracted the services of TheBiotechPanel, Inc., a comprehensive investor relations provider specializing in financial and investor relations and communications focused on Europe. The term of the agreement is for six months, however it was discontinued in March 2012.

### **Financial Instruments and Risks**

The Company is exposed to various financial instrument risks and assesses the impact and likelihood of this exposure. These risks include liquidity risk, credit risk, currency risk and interest rate risk. Where material, these risks are reviewed and monitored by the Board of Directors.

#### *Capital Management*

The Company manages its capital to safeguard the Company's ability to continue as a going concern, so that it can continue to provide adequate returns to shareholders and benefits to other stakeholders, and to have sufficient funds on hand for business opportunities as they arise.

The Company considers the items included in share capital as capital. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through short-term prospectuses, private placements, sell assets, incur debt, or return capital to shareholders. As at February 29, 2012, the Company does not have any debt and is not subject to externally imposed capital requirements.

#### *Interest Rate Risk*

Interest rate risk is the risk that the fair value of future cash flows from a financial instrument will fluctuate as a result in market interest rates. The Company is exposed to interest rate risk to the extent that the cash maintained at the financial institutions included in the Company's cash and cash equivalents are subject to a floating rate of interest. The interest rate risks on cash are not considered significant.

#### *Foreign Exchange Risk*

The Company incurs operating expenses and capital expenditures mostly in US dollars, with some operating expenses incurred in Canadian dollars which are subject to foreign currency fluctuations. The fluctuation of the US dollar in relation to Canadian dollars will have an impact upon the profitability of the Company and may also affect the value of the Company's assets and the amount of shareholders' equity. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. At February 29, 2012, the US dollar was equal to 0.99656 Canadian dollars. The currency risk is considered to be insignificant.

#### *Credit Risk*

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. Management's assessment of the Company's credit risk for cash and cash equivalents is low as cash and cash equivalents are held in financial institutions believed to be credit worthy. The Company limits its exposure to credit loss by placing its cash with major financial institutions and invests only in short-term obligations.

Approximately 99% of the Company's commercial sales and contract income during the six months ended February 29, 2012 were from two customers (2011 - 86% from one customer.). All of the grant revenue during the six months ended February 29, 2012 was received from NSF (2011 - 81 % from IRS grants and 19% from NSF).

Approximately 81 % of the Company's accounts receivables at February 29, 2012, were from one customer (August 31, 2011 - 25% from two customers; September 1, 2010 - 84% from two customers), and \$Nil were from the NSF grants (August 31, 2011 - 75%; September 1, 2010 - 16%).

While the Company is exposed to credit losses due to the non-performance of its counterparties, the Company considers the risk of this remote. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet.

### *Liquidity Risk*

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company attempts to manage liquidity risk by maintaining sufficient cash and cash equivalent balances. Liquidity requirements are managed based on expected cash flows to ensure that there is sufficient capital in order to meet short term obligations. As at February 29, 2012, the Company had a cash and cash equivalents balance of \$2,945,496 (August 31, 2011 - \$4,145,492; September 1, 2010 - \$2,003,296) to settle current liabilities of \$310,534 (August 31, 2011 - \$159,137; September 1, 2010 - \$420,610).

### *Fair Value*

The fair value of the Company's financial instruments is believed to equal the carrying amounts due to the short terms to maturity.

Fair value measurement disclosures include classification of financial instrument fair values in a fair value hierarchy comprising three levels reflecting the significance of the inputs used in making the measurements, described as follows:

- Level 1: Valuations based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: Valuations based on directly or indirectly observable inputs in active markets for similar assets or liabilities, other than Level 1 prices such as quoted interest or currency exchange rates; and
- Level 3: Valuations based on significant inputs that are not derived from observable market data, such as discounted cash flow methodologies based on internal cash flow forecasts.

The Company's fair value of cash and cash equivalents under the fair value hierarchy is measured using Level 1 inputs and fair value of the warrant liability is measured using Level 2 inputs.

### **Risks and Uncertainties**

Before making an investment decision with respect to the Company's common shares, investors should carefully consider the following risk factors, in addition to the other information included or incorporated by reference into the annual report for the fiscal years ended August 31, 2011, 2010 and 2009.

The primary risks that may affect the Company during this fiscal year are summarized below. If any of the following risks occur, the Company's business, results of operations or financial condition could be materially adversely affected:

- The Company expects to continue to experience losses as a result of its ongoing research. It is difficult to estimate the timing and future costs of its research and development programs and the timing of the achievement of milestone revenues.
- The Company may be unable to achieve certain milestones associated with the external partnerships, which could curtail future development and negatively impact the Company's share price.
- The Company does not currently have backup manufacturing capacity for some of its key products.
- The loss of a key supplier of certain raw materials could have a material adverse effect on the Company's business and financial condition.
- The Company may not achieve its projected development goals in the timeframes it announces and expects.
- Rapid technological change could make the Company's products obsolete.
- The Company faces uncertainties related to regulatory approval which could result in delays in product commercialization in certain territories.
- Even if the Company obtains marketing approval, its products will be subject to ongoing regulatory review.
- The Company's products, if approved, may fail to achieve market acceptance.
- Development of drugs can be costly and require years of research and development activities.
- If the Company cannot raise additional capital on acceptable terms, it may delay or be unable to pursue further development of its product portfolio, obtain regulatory approvals or commercialize its product candidates.
- If the Company is unable to protect its intellectual property rights, its competitors may develop and market products with similar features that may reduce demand for its products and the effective commercialization of its products may be inhibited.
- The Company may become involved in lawsuits with respect to collaborations or protection or enforcement of its patents that would be expensive and time consuming.
- If third-party manufacturers of the Company's products fail to devote sufficient time and resources to its concerns, or if their performance is substandard, clinical trials and product introductions may be delayed and its costs may rise.
- The Company may not be able to manufacture its products in commercial quantities, which would prevent it from marketing its products.
- The Company may not be able to successfully achieve its goals.

- The Company has international partners that expose it to additional business risks.
- The Company may incur losses associated with foreign currency fluctuations.
- The Company is subject to the risk of product liability claims, for which it may not have, or be able to obtain, adequate insurance coverage.
- Future sales of common shares by the Company or its existing lenders or shareholders may cause its share price to fall.
- The Company has never paid dividends on its common shares, and it does not anticipate paying cash dividends in the foreseeable future.

### Transition to International Financial Reporting Standards (“IFRS”)

Please refer to the February 29, 2012 unaudited condensed interim consolidated financial statements on [www.SEDAR.com](http://www.SEDAR.com) for details on the Company’s transition to IFRS.

- Note 3 – Significant Accounting Policies
- Note 15 – First Time Adoption of IFRS

### Management’s Responsibility for Financial Statements

The information provided in this report, including the financial statements, is the responsibility of management. In the preparation of these statements, estimates are sometimes necessary to make a determination of future values for certain assets or liabilities. Management believes such estimates have been based on careful judgments and have been properly reflected in the accompanying financial statements.

### Internal Controls Over Financial Reporting

Management has designed internal controls over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. Lack of optimal segregation of duties has been observed due to the relatively small size of the Company, but management believes that these weaknesses have been adequately mitigated through management and director oversight.

### Approval

The Board of Directors oversees management’s responsibility for financial reporting and internal control systems through an Audit Committee. This Committee meets periodically with management and annually with the independent auditors to review the scope and results of the annual audit and to review the financial statements and related financial reporting and internal control matters before the financial statements are approved by the Board of Directors and submitted to the shareholders of the Company. The Board of Directors of Stellar has approved the condensed interim consolidated financial statements and the disclosure contained in this MD&A. A copy of this MD&A will be provided to anyone who requests it.

### Other NID&A Requirements

Additional information is available on the Company’s website at [www.stellarbiotechnologies.com](http://www.stellarbiotechnologies.com) or on SEDAR at [www.SEDAR.com](http://www.SEDAR.com).

### Forward Looking Information

This MD&A contains certain forward-looking statements and information relating to the Company that are based on the beliefs of our management as well as assumptions made by and information currently available to us. When used in this document, the words “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to our company or our management, are intended to identify forward-looking statements. This MD&A contains forward-looking statements relating to, among other things, regulatory compliance, the sufficiency of current working capital, the estimated cost and availability of funding for the continued research and development of our products. Such statements reflect the current views of management with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or our achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements.

The Company does not believe it has any significant forward-looking information to report as at April 30, 2012.

### Outstanding Shares, Warrants And Stock Options

As at April 30, 2012, the Company had the following outstanding:

- 43,930,432 common shares
- Warrants:

CDN		
Exercise Price	Number of Warrants	Expiry Date
\$1.15	6,213,000	November 14, 2012
\$0.60	345,600	November 14, 2012
\$0.50	1,500,000	March 28, 2013
	8,058,600	

· stock options:

CDN Exercise Price	Number of Options	Expiry Date
\$0.28	2,431,667	April 9, 2017
\$0.25	75,000	May 17, 2017
\$0.28	70,000	June 17, 2017
\$0.28	20,000	June 28, 2017
\$0.28	70,000	July 13, 2017
\$0.64	70,000	October 25, 2017
\$1.00	60,000	February 10, 2018
\$1.00	23,333	March 8, 2018
\$0.65	1,329,600	August 8, 2018
\$0.50	5,000	September 26, 2018
\$0.40	80,000	December 22, 2018
\$0.42	5,000	February 16, 2019
\$0.42	1,279,600	April 13, 2019
\$0.42	50,000	April 26, 2019
	5,569,200	

### Contingencies

There are no contingent liabilities.

### Proposed Transactions

There are no proposed transactions that have not been disclosed herein.

### Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

### Critical Accounting Estimates

The preparation of financial statements in accordance with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual reports could differ from management's estimates.

## CORPORATE DATA APRIL 30, 2012

### HEAD OFFICE

Stellar Biotechnologies, Inc.  
342 E. Scott Street  
Port Hueneme, CA 93041 USA  
Tel: (805) 488-2147  
Fax: (805) 488-2889

Canadian Regulatory Address  
1868 King George Boulevard  
South Surrey, BC, V4A 5A1  
Canada  
Tel: 604-306-8854  
Fax: 604-535-4454

### REGISTRAR & TRANSFER AGENT

Computershare Investor Services Inc.  
3rd floor, 510 Burrard Street  
Vancouver, B.C.,  
Canada V6C 3B9

### DIRECTORS, OFFICERS AND KEY EMPLOYEES

### SOLICITOR

McMillan LLP  
1500 - 1055 West Georgia Street  
Vancouver, BC V6E 4N7  
Tel: 604-691-7452  
Fax: 604-691-7356

### AUDITORS

D & H Group LLP  
Chartered Accountants  
10th floor, 1333 West Broadway  
Vancouver, BC V6H 4C1  
Tel: 604-731-5881  
Fax: 604-731-9923  
info@dhgroup.com

### INVESTOR CONTACTS

Frank Oakes  
Darrell Brookstein  
dbrookstein@stellarbiotech.com

President, CEO and Director  
Executive VP Corporate

Darrell Brookstein  
Tel: (805) 488-2800 ext. 103  
Email:

Daniel E. Morse, Ph.D  
David L. Hill Ph.D  
Malcolm Gefter Ph.D  
Scott Davis  
Herbert S. Chow, Ph.D  
John S. Sundsmo, Ph.D  
Catherine Brisson, Ph.D

Corporate Secretary and Director  
Director  
Director  
Director  
Chief Financial Officer  
VP Product Development  
VP Research & IP Management  
Director of Quality Assurance and  
Regulatory Affairs

## **LISTING**

TSX Venture Exchange  
Trading Symbol: KLH  
CUSIP #: 85855A104

**Form 52-109FV2**  
**Certification of Interim Filings**  
**Venture Issuer Basic Certificate**

I, Frank R. Oakes, Chief Executive Officer, Stellar Biotechnologies, Inc. certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Stellar Biotechnologies, Inc. (the “issuer”) for the interim period ended February 29, 2012.
2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

Date: April 30, 2012.

“Frank R. Oakes”

FRANK R. OAKES  
Chief Executive Officer

**NOTE TO READER**

In contrast to the certificate required for non-venture issuers under National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings* (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of

- i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

The issuer’s certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52- 109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

**Form 52-109FV2**  
**Certification of Interim Filings**  
**Venture Issuer Basic Certificate**

I, Scott Davis, Chief Financial Officer, Stellar Biotechnologies, Inc. certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Stellar Biotechnologies, Inc. (the “issuer”) for the interim period ended February 29, 2012.
2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

Date: April 30, 2012.

“Scott Davis”

SCOTT DAVIS

Chief Financial Officer

**NOTE TO READER**

In contrast to the certificate required for non-venture issuers under National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings* (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of

- i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

The issuer’s certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52- 109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.